Publications
2024
TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival.
Lascaux, P., Hoslett, G., Tribble, S., Trugenberger, C., Antičević, I., Otten, C., . . . Ramadan, K. (2024). TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival.. Cell, 187(20), 5698-5718.e26. doi:10.1016/j.cell.2024.08.020
Adaptive MR-Guided Stereotactic Ablative Body Radiotherapy (MRgSABR) for Pancreas Cancer: Dosimetric Evaluation from EMERALD Trial
Moreno-Olmedo, E., George, B., Teoh, S., Owens, R., Swan, L., Good, J., . . . Mukherjee, S. (2024). Adaptive MR-Guided Stereotactic Ablative Body Radiotherapy (MRgSABR) for Pancreas Cancer: Dosimetric Evaluation from EMERALD Trial. International Journal of Radiation Oncology*Biology*Physics, 120(2), e473-e474. doi:10.1016/j.ijrobp.2024.07.1053
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
Mukherjee, S., Qi, C., Shaw, R., Jones, C. M., Bridgewater, J. A., Radhakrishna, G., . . . Corrie, P. (2024). Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.. European journal of cancer (Oxford, England : 1990), 209, 114236. doi:10.1016/j.ejca.2024.114236
Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.
Nugent, K., Mukherjee, S., Teoh, S., George, B., Martin, A., Gaya, A., . . . Good, J. (2024). Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.. Clinical oncology (Royal College of Radiologists (Great Britain)), 36(9), 576-584. doi:10.1016/j.clon.2024.05.012
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.
Beach, C., MacLean, D., Majorova, D., Melemenidis, S., Nambiar, D. K., Kim, R. K., . . . Olcina, M. M. (2024). Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.. The Journal of clinical investigation, 134(16), e185067. doi:10.1172/jci185067
Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors.
Domingo, E., Rathee, S., Blake, A., Samuel, L., Murray, G., Sebag-Montefiore, D., . . . Maughan, T. S. (2024). Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors.. EBioMedicine, 106, 105228. doi:10.1016/j.ebiom.2024.105228
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen, R., Raeisi, M., Chibaudel, B., Shi, Q., Yoshino, T., Zalcberg, J. R., . . . de Gramont, A. (2024). Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.. European journal of cancer (Oxford, England : 1990), 207, 114160. doi:10.1016/j.ejca.2024.114160
Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures.
Mahmood, U., Blake, A., Rathee, S., Samuel, L., Murray, G., Sebag-Montefiore, D., . . . Domingo, E. (2024). Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures.. Cancer research communications, 4(7), 1765-1776. doi:10.1158/2767-9764.crc-23-0502
Cluster Triplet Loss for Unsupervised Domain Adaptation on Histology Images
Wood, R., Domingo, E., Koelzer, V. H., Maughan, T. S., & Rittscher, J. (2024). Cluster Triplet Loss for Unsupervised Domain Adaptation on Histology Images. In 2024 IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) (pp. 5122-5131). IEEE. doi:10.1109/cvprw63382.2024.00519
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., . . . Dunne, P. D. (2024). Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.. Nature genetics, 56(6), 1321. doi:10.1038/s41588-024-01809-4
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis, C. S., Liu, H., Sorich, M. J., Pederson, L. D., Van Cutsem, E., Maughan, T., . . . Shi, Q. (2024). Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.. British journal of cancer, 130(8), 1269-1278. doi:10.1038/s41416-024-02604-y
Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy.
Lafarge, M. W., Domingo, E., Sirinukunwattana, K., Wood, R., Samuel, L., Murray, G., . . . Koelzer, V. H. (2024). Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy.. NPJ precision oncology, 8(1), 89. doi:10.1038/s41698-024-00580-3
New role of fat-free mass in cancer risk linked with genetic predisposition.
Harris, B. H. L., Di Giovannantonio, M., Zhang, P., Harris, D. A., Lord, S. R., Allen, N. E., . . . Buffa, F. M. (2024). New role of fat-free mass in cancer risk linked with genetic predisposition.. Scientific reports, 14(1), 7270. doi:10.1038/s41598-024-54291-7
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., . . . Dunne, P. D. (2024). Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.. Nature genetics, 56(3), 458-472. doi:10.1038/s41588-024-01654-5
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed, S. R., Lord, S., El Badri, S., Harman, R., Holmes, J., Kamzi, F., . . . Hawkins, M. A. (2024). CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.. British journal of cancer, 130(3), 467-475. doi:10.1038/s41416-023-02542-1
7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis
Raeisi, M., Cohen, R., Chibaudel, B., Hurwitz, H., Saltz, L., Kabbinavar, F., . . . De Gramont, A. (2024). 7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis. ESMO Open, 9, 102262. doi:10.1016/j.esmoop.2024.102262
2023
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.
Beach, C., MacLean, D., Majorova, D., Melemenidis, S., Nambiar, D. K., Kim, R. K., . . . Olcina, M. M. (2023). Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.. The Journal of clinical investigation, 133(23), e168277. doi:10.1172/jci168277
Image-Based Consensus Molecular Subtyping in Rectal Cancer Biopsies and Response to Neoadjuvant Chemoradiotherapy
A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR)
O'Cathail, S. M., Qiao, M., Muirhead, R., Adams, R., Rao, S., Fisher, K., . . . Hawkins, M. A. (2023). A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR). International Journal of Radiation Oncology*Biology*Physics, 117(2), e329-e330. doi:10.1016/j.ijrobp.2023.06.2379
Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel
Shen, Z., Brand, D., Zhang, Y., Simard, M., Lopes, A., Miles, E., . . . Hawkins, M. A. (2023). Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel. International Journal of Radiation Oncology*Biology*Physics, 117(2), e338. doi:10.1016/j.ijrobp.2023.06.2397
Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.
Teoh, S., Ooms, A., George, B., Owens, R., Chu, K. -Y., Drabble, J., . . . Mukherjee, S. (2023). Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.. BMJ open, 13(9), e068906. doi:10.1136/bmjopen-2022-068906
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
Katipally, R. R., Martinez, C. A., Pugh, S. A., Bridgewater, J. A., Primrose, J. N., Domingo, E., . . . with the S:CORT Consortium. (2023). Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.. JAMA oncology, 9(9), 1245-1254. doi:10.1001/jamaoncol.2023.2535
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.
Richman, S. D., Hemmings, G., Roberts, H., Gallop, N., Dodds, R., Wilkinson, L., . . . Adams, R. (2023). FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing.. Journal of clinical pathology, 76(8), 548-554. doi:10.1136/jclinpath-2022-208233
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.
Mukherjee, S., Hurt, C. N., Adams, R., Bateman, A., Bradley, K. M., Bridges, S., . . . Crosby, T. D. L. (2023). Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.. EClinicalMedicine, 61, 102059. doi:10.1016/j.eclinm.2023.102059
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
Palles, C., Lucas, M., Watts, K., Galavotti, S., Chin, I. S., Campbell, C., . . . Cheadle, J. (2023). A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.. Journal of Clinical Oncology, 41(16_suppl), 3028. doi:10.1200/jco.2023.41.16_suppl.3028
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.
Pugh, S. A., Domingo, E., Richman, S. D., Dunne, P. D., Redmond, K., Blake, A., . . . Bridgewater, J. A. (2023). Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.. Journal of Clinical Oncology, 41(16_suppl), 3577. doi:10.1200/jco.2023.41.16_suppl.3577
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Kopetz, S., Yoshino, T., Kim, T. W., Wasan, H. S., Van Cutsem, E., Ciardiello, F., . . . Tabernero, J. (2023). BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 41(16_suppl), TPS3627. doi:10.1200/jco.2023.41.16_suppl.tps3627
Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.
Wills, C., Watts, K., Maughan, T. S., Fisher, D., Al-Tassan, N. A., Houlston, R. S., . . . Cheadle, J. P. (2023). Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.. Genes, chromosomes & cancer, 62(6), 332-341. doi:10.1002/gcc.23133
Next generation radiotheranostics promoting precision medicine.
Pomykala, K. L., Hadaschik, B. A., Sartor, O., Gillessen, S., Sweeney, C. J., Maughan, T., . . . Herrmann, K. (2023). Next generation radiotheranostics promoting precision medicine.. Annals of oncology : official journal of the European Society for Medical Oncology, 34(6), 507-519. doi:10.1016/j.annonc.2023.03.001
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen, R., Raeisi, M., Shi, Q., Chibaudel, B., Yoshino, T., Zalcberg, J. R., . . . De Gramont, A. (2023). Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.. Journal of Clinical Oncology, 41(16_suppl), 3554. doi:10.1200/jco.2023.41.16_suppl.3554
OC-0103 SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer
Mukherjee, S., Hurt, C., Gwynne, S., Nixon, L., Bridges, S., Adams, R., . . . Crosby, T. (2023). OC-0103 SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer. Radiotherapy and Oncology, 182, S64-S65. doi:10.1016/s0167-8140(23)08517-1
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Punt, C. J. A., Heinemann, V., Maughan, T., Cremolini, C., Van Cutsem, E., McDermott, R., . . . Pfeiffer, P. (2023). Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.. ESMO open, 8(2), 101199. doi:10.1016/j.esmoop.2023.101199
Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.
Fernandez-Rozadilla, C., Timofeeva, M., Chen, Z., Law, P., Thomas, M., Schmit, S., . . . Peters, U. (2023). Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.. Nature genetics, 55(3), 519-520. doi:10.1038/s41588-023-01334-w
Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation.
Samant, P., Ruysscher, D. D., Hoebers, F., Canters, R., Hall, E., Nutting, C., . . . Van den Heuvel, F. (2023). Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation.. Clinical and translational radiation oncology, 39, 100595. doi:10.1016/j.ctro.2023.100595
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer (mCRC).
Kopetz, S., Yoshino, T., Kim, T. W., Yaeger, R., Desai, J., Wasan, H. S., . . . Tabernero, J. (2023). BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 41(4_suppl), 119. doi:10.1200/jco.2023.41.4_suppl.119
Global colorectal cancer research, 2007-2021: Outputs and funding.
Begum, M., Lewison, G., Wang, X., Dunne, P. D., Maughan, T., Sullivan, R., & Lawler, M. (2023). Global colorectal cancer research, 2007-2021: Outputs and funding.. International journal of cancer, 152(3), 470-479. doi:10.1002/ijc.34279
Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., Cammareri, P., . . . Sansom, O. J. (2023). Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.. Nature communications, 14(1), 522. doi:10.1038/s41467-023-36266-w
Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.
Fernandez-Rozadilla, C., Timofeeva, M., Chen, Z., Law, P., Thomas, M., Schmit, S., . . . Peters, U. (2023). Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.. Nature genetics, 55(1), 89-99. doi:10.1038/s41588-022-01222-9
Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies
Wood, R., Domingo, E., Sirinukunwattana, K., Lafarge, M. W., Koelzer, V. H., Maughan, T. S., & Rittscher, J. (2023). Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies. In Unknown Conference (pp. 758-767). Springer Nature Switzerland. doi:10.1007/978-3-031-43904-9_73
Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease.
Wills, C., Houseman, A., Watts, K., Maughan, T. S., Fisher, D., Houlston, R. S., . . . Cheadle, J. P. (2023). Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease.. BJC reports, 1(1), 2. doi:10.1038/s44276-023-00003-z
2022
Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gunduz, N., Gentaz, P., Cammareri, P., . . . Sansom, O. J. (2022). Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.. Nature communications, 13(1), 7551. doi:10.1038/s41467-022-35134-3
Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.
Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., . . . Dunne, P. D. (2022). Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.. Gut, 71(12), 2502-2517. doi:10.1136/gutjnl-2021-326183
Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
Brown, L. C., Fisher, D., Adams, R., Seligmann, J., Seymour, M., Kaplan, R., . . . Maughan, T. S. (2022). Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT.
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.
Gil Vazquez, E., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., . . . Leedham, S. J. (2022). Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.. Cell stem cell, 29(11), 1612. doi:10.1016/j.stem.2022.09.005
Dosimetric Impact of Gastrointestinal Tract Variability during Online Adaptive MR-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas
Teoh, S., George, B., Owens, R., Bungay, H., Maughan, T. S., & Mukherjee, S. (2022). Dosimetric Impact of Gastrointestinal Tract Variability during Online Adaptive MR-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas. International Journal of Radiation Oncology*Biology*Physics, 114(3), e599. doi:10.1016/j.ijrobp.2022.07.2293
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy.
Spurr, L. F., Martinez, C. A., Katipally, R. R., Iyer, S. C., Pugh, S. A., Bridgewater, J. A., . . . Pitroda, S. P. (2022). A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy.. NPJ precision oncology, 6(1), 72. doi:10.1038/s41698-022-00318-z
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
Hashimoto, T., Takayanagi, D., Yonemaru, J., Naka, T., Nagashima, K., Yatabe, Y., . . . Sekine, S. (2022). Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.. British journal of cancer, 127(6), 1043-1050. doi:10.1038/s41416-022-01880-w
Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data.
Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C., Legrini, A., Cameron, A. J., . . . Dunne, P. D. (2022). Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data.. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(18), 4056-4069. doi:10.1158/1078-0432.ccr-22-1102
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Watts, K., Wills, C., Madi, A., Palles, C., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2022). Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.. International journal of cancer, 151(6), 957-966. doi:10.1002/ijc.34046
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love, S. B., Cafferty, F., Snowdon, C., Carty, K., Savage, J., Pallmann, P., . . . Sydes, M. R. (2022). Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.. Trials, 23(1), 757. doi:10.1186/s13063-022-06680-4
337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials
Hassanieh, S., Domingo, E., Blake, A., Fisher, D., Redmond, K. L., Richman, S. D., . . . Maughan, T. (2022). 337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials. Annals of Oncology, 33, S691. doi:10.1016/j.annonc.2022.07.475
LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
Tabernero, J., Yoshino, T., Kim, T. W., Yaeger, R., Desai, J., Wasan, H. S., . . . Kopetz, S. (2022). LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). Annals of Oncology, 33, S1392-S1393. doi:10.1016/j.annonc.2022.08.022
Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer.
Henderson, R. H., French, D., McFerran, E., Adams, R., Wasan, H., Glynne-Jones, R., . . . Lawler, M. (2022). Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer.. Journal of cancer policy, 33, 100342. doi:10.1016/j.jcpo.2022.100342
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.
Vasquez, E. G., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., . . . Leedham, S. J. (2022). Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.. Cell stem cell, 29(8), 1213-1228.e8. doi:10.1016/j.stem.2022.07.008
Importance of clinical research for the UK's 10-year cancer plan
Lee, R. W., Danson, S., Elliot, M., Park, E. I., Pinkney, T. D., Shaw, C. E., . . . Wadsley, J. (2022). Importance of clinical research for the UK's 10-year cancer plan. LANCET ONCOLOGY, 23(8), 975-978. doi:10.1016/S1470-2045(22)00292-3
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.
Goldberg, R. M., Adams, R., Buyse, M., Eng, C., Grothey, A., André, T., . . . de Gramont, A. (2022). Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.. Journal of the National Cancer Institute, 114(6), 819-828. doi:10.1093/jnci/djab218
Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture
Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities.
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M., Ryan, A., . . . Giaccia, A. (2022). Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities.. Physics in medicine and biology, 67(12). doi:10.1088/1361-6560/ac71ef
First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.
Shmueli, E. S., Raeisi, M., Chibaudel, B., Maughan, T. S., Douillard, J. -Y., Van Cutsem, E., . . . De Gramont, A. (2022). First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. Journal of Clinical Oncology, 40(16_suppl), 3578. doi:10.1200/jco.2022.40.16_suppl.3578
O40 Impact of TGFβ inhibition and radiotherapy in a heterotopic rectal cancer mouse model
Beach, C., Mul, E., Belnoue-Davis, H., Valbuena, G., Molino, M. O. D., Maughan, T., & Leedham, S. (2022). O40 Impact of TGFβ inhibition and radiotherapy in a heterotopic rectal cancer mouse model. In Oral presentations (pp. A24.1-A24). BMJ Publishing Group Ltd and British Society of Gastroenterology. doi:10.1136/gutjnl-2022-bsg.40
Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.
Jin, Z., Dixon, J. G., Hubbard, J. M., Eng, C., Lieu, C. H., Douillard, J. -Y., . . . Shi, Q. (2022). Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 40(16_suppl), 3572. doi:10.1200/jco.2022.40.16_suppl.3572
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
Seligmann, J. F., Domingo, E., Fisher, D., Elliott, F., Brown, L. C., Seymour, M. T., . . . Maughan, T. (2022). The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 40(16_suppl), 3540. doi:10.1200/jco.2022.40.16_suppl.3540
OC-0103 SCALOP2:A multicenter randomized trial of RT dose escalation and nelfinavir in pancreatic cancer
Mukherjee, S., Qi, C., Shaw, R., Bridgewater, J., Radhakrishna, G., Patel, N., . . . Corrie, P. (2022). OC-0103 SCALOP2:A multicenter randomized trial of RT dose escalation and nelfinavir in pancreatic cancer. Radiotherapy and Oncology, 170, S77-S78. doi:10.1016/s0167-8140(22)02479-3
PO-1755 Machine Learning in NTCP prediction --- A superior alternative to the Lyman-Burman-Kutcher model
Samant, P., Maughan, T., Van Den Heuvel, F., Canters, R., Hoebers, F., Hall, E., . . . de Ruysscher, D. (2022). PO-1755 Machine Learning in NTCP prediction --- A superior alternative to the Lyman-Burman-Kutcher model. Radiotherapy and Oncology, 170, S1558-S1560. doi:10.1016/s0167-8140(22)03719-7
Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data
Reply to A. Kurreck et al and M.S. Copur et al.
Adams, R., Wilson, R., Brown, L., & Maughan, T. (2022). Reply to A. Kurreck et al and M.S. Copur et al.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(11), 1263-1264. doi:10.1200/jco.21.02806
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
Brown, L. C., Graham, J., Fisher, D., Adams, R., Seligmann, J., Seymour, M., . . . FOCUS4 Trial Investigators. (2022). Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.. Clinical trials (London, England), 19(2), 146-157. doi:10.1177/17407745211069879
Practical Guidance for Running Late-Phase Platform Protocols for Clinical Trials: Lessons From Experienced UK Clinical Trials Units
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
Papamichael, D., Lopes, G. S., Olswold, C. L., Douillard, J. -Y., Adams, R. A., Maughan, T. S., . . . Shi, Q. (2022). Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.. European journal of cancer (Oxford, England : 1990), 163, 1-15. doi:10.1016/j.ejca.2021.12.007
Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data.
Ahmaderaghi, B., Amirkhah, R., Jackson, J., Lannagan, T. R. M., Gilroy, K., Malla, S. B., . . . Dunne, P. D. (2022). Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data.. Disease models & mechanisms, 15(3), dmm049257. doi:10.1242/dmm.049257
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of <i>BRAF</i> V600E-mutant (<i>BRAF</i><sup>V600E</sup>) metastatic colorectal cancer (mCRC).
Kopetz, S., Yoshino, T., Kim, T. W., Desai, J., Yaeger, R., Van Cutsem, E., . . . Tabernero, J. (2022). BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of <i>BRAF</i> V600E-mutant (<i>BRAF</i><sup>V600E</sup>) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 40(4_suppl), 134. doi:10.1200/jco.2022.40.4_suppl.134
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of <i>BRAF</i> V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2022). BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of <i>BRAF</i> V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 40(4_suppl), TPS211. doi:10.1200/jco.2022.40.4_suppl.tps211
Enhancing Local Context of Histology Features in Vision Transformers
Wood, R., Sirinukunwattana, K., Domingo, E., Sauer, A., Lafarge, M. W., Koelzer, V. H., . . . Rittscher, J. (2022). Enhancing Local Context of Histology Features in Vision Transformers. In Unknown Conference (pp. 154-163). Springer Nature Switzerland. doi:10.1007/978-3-031-19660-7_15
2021
A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.
Wills, C., He, Y., Summers, M. G., Lin, Y., Phipps, A. I., Watts, K., . . . Cheadle, J. P. (2021). A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.. European journal of cancer (Oxford, England : 1990), 159, 247-258. doi:10.1016/j.ejca.2021.09.047
Stromal composition predicts recurrence of early rectal cancer after local excision.
Jones, H. J. S., Cunningham, C., Askautrud, H. A., Danielsen, H. E., Kerr, D. J., Domingo, E., . . . Koelzer, V. H. (2021). Stromal composition predicts recurrence of early rectal cancer after local excision.. Histopathology, 79(6), 947-956. doi:10.1111/his.14438
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
Yin, J., Cohen, R., Jin, Z., Liu, H., Pederson, L., Adams, R., . . . Lenz, H. -J. (2021). Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.. Journal of the National Cancer Institute, 113(12), 1705-1713. doi:10.1093/jnci/djab112
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Adams, R. A., Fisher, D. J., Graham, J., Seligmann, J. F., Seymour, M., Kaplan, R., . . . FOCUS4 Trial Investigators. (2021). Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3693-3704. doi:10.1200/jco.21.01436
Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., . . . FOCUS4 Trial Investigators. (2021). Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3705-3715. doi:10.1200/jco.21.01435
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Watts, K., Wills, C., Madi, A., Palles, C., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2021). Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.. International journal of cancer, 149(9), 1713-1722. doi:10.1002/ijc.33739
Modelling of Dosimetric Impact of Visceral Organ Variability During MRI-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas.
Teoh, S., Chu, K. Y., Robinson, M., Whyntie, T., Heuvel, F. V. D., Mukherjee, S., & Maughan, T. S. (2021). Modelling of Dosimetric Impact of Visceral Organ Variability During MRI-Guided Hypofractionated Stereotactic Ablative Radiotherapy (SABR) to the Pancreas.. International journal of radiation oncology, biology, physics, 111(3S), e556-e557. doi:10.1016/j.ijrobp.2021.07.1508
Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
Ten Hoorn, S., Sommeijer, D. W., Elliott, F., Fisher, D., de Back, T. R., Trinh, A., . . . Vermeulen, L. (2021). Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.. British journal of cancer, 125(8), 1080-1088. doi:10.1038/s41416-021-01477-9
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Cohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T. S., . . . André, T. (2021). BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.. Journal of the National Cancer Institute, 113(10), 1386-1395. doi:10.1093/jnci/djab042
Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases
382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring
Seligmann, J., Fisher, D. J., Brown, L. C., Adams, R., Graham, J., Quirke, P., . . . Maughan, T. (2021). 382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Annals of Oncology, 32, S530. doi:10.1016/j.annonc.2021.08.904
430P Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer
Graham, J., Brown, L. C., Adams, R. A., Seligmann, J., Wilson, R., & Maughan, T. (2021). 430P Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer. Annals of Oncology, 32, S549. doi:10.1016/j.annonc.2021.08.951
431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)
Adams, R. A., Fisher, D. J., Graham, J., Seligmann, J., Seymour, M., Kaplan, R. S., . . . Maughan, T. (2021). 431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 32, S549. doi:10.1016/j.annonc.2021.08.952
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.
Henderson, R. H., French, D., Maughan, T., Adams, R., Allemani, C., Minicozzi, P., . . . Lawler, M. (2021). The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.. The lancet. Gastroenterology & hepatology, 6(9), 709-722. doi:10.1016/s2468-1253(21)00147-3
The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.
Naszai, M., Kurjan, A., & Maughan, T. S. (2021). The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: A systematic review and meta-analysis.. Cancer medicine, 10(17), 5983-5997. doi:10.1002/cam4.4143
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.
Adams, R., Goey, K., Chibaudel, B., Koopman, M., Punt, C., Arnold, D., . . . Fisher, D. (2021). Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.. Cancer treatment reviews, 99, 102226. doi:10.1016/j.ctrv.2021.102226
NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch.
O'Cathail, S. M., Wu, C. -H., Thomas, R., Hawkins, M. A., Maughan, T. S., & Lewis, A. (2021). NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch.. Antioxidants (Basel, Switzerland), 10(9), 1380. doi:10.3390/antiox10091380
The Molecular Subtyping Resource (MouSR): a user-friendly tool for rapid biological discovery from human or mouse transcriptional data
Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial.
Mukherjee, S., Hurt, C., Radhakrishna, G., Gwynne, S., Bateman, A., Gollins, S., . . . Crosby, T. D. L. (2021). Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial.. European journal of cancer (Oxford, England : 1990), 153, 153-161. doi:10.1016/j.ejca.2021.05.020
PO-1793 Quantifying the oxygen fixation mechanism in charged particle beams
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M., & Maughan, T. (2021). PO-1793 Quantifying the oxygen fixation mechanism in charged particle beams. Radiotherapy and Oncology, 161, S1519. doi:10.1016/s0167-8140(21)08244-x
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres, M., Lanfredini, S., Xu, H., Burns, A., Blake, A., Willenbrock, F., . . . O'Neill, E. (2021). TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.. Gastroenterology, 161(2), 653-668.e16. doi:10.1053/j.gastro.2021.04.044
Incorporating oxygenation levels in analytical DNA-damage models-quantifying the oxygen fixation mechanism.
Van den Heuvel, F., Vella, A., Fiorini, F., Brooke, M., Hill, M. A., & Maughan, T. (2021). Incorporating oxygenation levels in analytical DNA-damage models-quantifying the oxygen fixation mechanism.. Physics in medicine and biology, 66(14). doi:10.1088/1361-6560/ac0b80
Abstract LB129: Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies
Domingo, E., Rathee, S., Blake, A., Samuel, L. M., Murray, G. I., Sebag-Montefiore, D., . . . Maughan, T. (2021). Abstract LB129: Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies. Cancer Research, 81(13_Supplement), LB129. doi:10.1158/1538-7445.am2021-lb129
Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.
Leach, J. D. G., Vlahov, N., Tsantoulis, P., Ridgway, R. A., Flanagan, D. J., Gilroy, K., . . . Sansom, O. J. (2021). Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.. Nature communications, 12(1), 3464. doi:10.1038/s41467-021-23717-5
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of <i>BRAF</i> V600E-mutant (<i>BRAF</i><sup>V600E</sup>) metastatic colorectal cancer (mCRC).
Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2021). BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of <i>BRAF</i> V600E-mutant (<i>BRAF</i><sup>V600E</sup>) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 39(15_suppl), TPS3619. doi:10.1200/jco.2021.39.15_suppl.tps3619
Global <i>BRAF</i> testing practices in metastatic colorectal cancer (mCRC).
Desai, J., Kopetz, S., Grothey, A., Ciardiello, F., Kim, T. W., Maughan, T., . . . Tabernero, J. (2021). Global <i>BRAF</i> testing practices in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 39(15_suppl), e15523. doi:10.1200/jco.2021.39.15_suppl.e15523
Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
Adams, R., Fisher, D., Graham, J., Seligmann, J. F., Seymour, M., Kaplan, R. S., . . . Maughan, T. (2021). Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.. Journal of Clinical Oncology, 39(15_suppl), 3504. doi:10.1200/jco.2021.39.15_suppl.3504
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang, P., Kitchen-Smith, I., Xiong, L., Stracquadanio, G., Brown, K., Richter, P. H., . . . Bond, G. L. (2021). Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.. Cancer research, 81(7), 1667-1680. doi:10.1158/0008-5472.can-20-0177
Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
Culliford, R., Cornish, A. J., Law, P. J., Farrington, S. M., Palin, K., Jenkins, M. A., . . . Houlston, R. S. (2021). Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.. British journal of cancer, 124(6), 1169-1174. doi:10.1038/s41416-020-01211-x
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Sirinukunwattana, K., Domingo, E., Richman, S. D., Redmond, K. L., Blake, A., Verrill, C., . . . S:CORT consortium. (2021). Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.. Gut, 70(3), 544-554. doi:10.1136/gutjnl-2019-319866
Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA.
Whalley, C., Payne, K., Domingo, E., Blake, A., Richman, S., Brooks, J., . . . Beggs, A. D. (2021). Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA.. Epigenomes, 5(1), 6. doi:10.3390/epigenomes5010006
The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors.
van Bijsterveldt, L., Durley, S. C., Maughan, T. S., & Humphrey, T. C. (2021). The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 937-962. doi:10.1158/1078-0432.ccr-20-3358
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock, F., Cox, C. M., Parkes, E. E., Wilhelm-Benartzi, C. S., Abraham, A. G., Owens, R., . . . Mukherjee, S. (2021). Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.. British journal of cancer, 124(3), 581-586. doi:10.1038/s41416-020-01120-z
Global BRAF testing practices in metastatic colorectal cancer.
Kopetz, S., Grothey, A., Ciardiello, F., Desai, J., Kim, T. W., Maughan, T., . . . Tabernero, J. (2021). Global BRAF testing practices in metastatic colorectal cancer.. Journal of Clinical Oncology, 39(3_suppl), 128. doi:10.1200/jco.2021.39.3_suppl.128
Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.
Weinberg, B. A., Rakez, M., Chibaudel, B., Maughan, T., Adams, R., Zalcberg, J. R., . . . Deming, D. A. (2021). Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.. Journal of Clinical Oncology, 39(3_suppl), 108. doi:10.1200/jco.2021.39.3_suppl.108
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.
Yin, J., Dawood, S., Cohen, R., Meyers, J., Zalcberg, J., Yoshino, T., . . . Adams, R. (2021). Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.. Therapeutic advances in medical oncology, 13, 17588359211020547. doi:10.1177/17588359211020547
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Malla, S. B., Fisher, D. J., Domingo, E., Blake, A., Hassanieh, S., Redmond, K. L., . . . S:CORT consortium. (2021). In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(1), 288-300. doi:10.1158/1078-0432.ccr-20-3237
2020
Oxygen Related Factors in FLASH Radiotherapy
Van Den Heuvel, F., Petersson, K., Vojnovic, B., Hill, M., Vella, A., Ryan, A., . . . Giaccia, A. J. (2020). Oxygen Related Factors in FLASH Radiotherapy. International Journal of Radiation Oncology*Biology*Physics, 108(3), e534. doi:10.1016/j.ijrobp.2020.07.1668
TET2 drives 5hmc marking of<i>GATA6</i>and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.
Craig, S. G., Humphries, M. P., Alderdice, M., Bingham, V., Richman, S. D., Loughrey, M. B., . . . Salto-Tellez, M. (2020). Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.. British journal of cancer, 123(8), 1280-1288. doi:10.1038/s41416-020-0985-5
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.
Viratham Pulsawatdi, A., Craig, S. G., Bingham, V., McCombe, K., Humphries, M. P., Senevirathne, S., . . . Salto-Tellez, M. (2020). A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.. Molecular oncology, 14(10), 2384-2402. doi:10.1002/1878-0261.12764
Fusobacterium nucleatum, rectal cancer and radiotherapy.
Mann, E. H., & Maughan, T. S. (2020). Fusobacterium nucleatum, rectal cancer and radiotherapy.. Annals of oncology : official journal of the European Society for Medical Oncology, 31(10), 1277-1278. doi:10.1016/j.annonc.2020.06.019
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.
O'Cathail, S. M., Wu, C. -H., Lewis, A., Holmes, C., Hawkins, M. A., & Maughan, T. (2020). NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.. Cancer genetics, 248-249, 1-10. doi:10.1016/j.cancergen.2020.08.006
432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database
Papamichael, D., Lopes, G. S., Olswold, C. L., Chibaudel, B., Zalcberg, J. R., Van Cutsem, E., . . . Shi, Q. (2020). 432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database. Annals of Oncology, 31, S425. doi:10.1016/j.annonc.2020.08.543
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial.
Barber, P. R., Weitsman, G., Lawler, K., Barrett, J. E., Rowley, M., Rodriguez-Justo, M., . . . Ng, T. (2020). HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial.. Journal of the National Cancer Institute, 112(9), 944-954. doi:10.1093/jnci/djz231
Abstract 3867: STAT1-related antigen processing and presentation dictates prognosis in the fibroblast-rich subtype of stage II/III colon cancer
McCorry, A. M., Leonard, N. A., Jackstadt, R., Flanagan, D. J., Sansom, O. J., Maughan, T., . . . Dunne, P. D. (2020). Abstract 3867: STAT1-related antigen processing and presentation dictates prognosis in the fibroblast-rich subtype of stage II/III colon cancer. Cancer Research, 80(16_Supplement), 3867. doi:10.1158/1538-7445.am2020-3867
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer.
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., . . . Powrie, F. (2020). The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(16), 4313-4325. doi:10.1158/1078-0432.ccr-19-1086
A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).
O'Cathail, S. M., Davis, S., Holmes, J., Brown, R., Fisher, K., Seymour, L., . . . Hawkins, M. A. (2020). A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).. Radiation oncology (London, England), 15(1), 151. doi:10.1186/s13014-020-01593-5
Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.
Kleeman, S. O., Koelzer, V. H., Jones, H. J., Vazquez, E. G., Davis, H., East, J. E., . . . Leedham, S. J. (2020). Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification.. Gut, 69(6), 1092-1103. doi:10.1136/gutjnl-2019-319126
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019)
Ren, L., Zhu, D., Benson, A. B. I. I. I., Nordlinger, B., Koehne, C. -H., Delaney, C. P., . . . Xu, J. (2020). Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). EJSO, 46(6), 955-966. doi:10.1016/j.ejso.2020.02.019
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
Karapetis, C. S., Liu, H., Sorich, M., Fiskum, J., Grothey, A., Van Cutsem, E., . . . Shi, Q. (2020). Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.. Journal of Clinical Oncology, 38(15_suppl), 4090. doi:10.1200/jco.2020.38.15_suppl.4090
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Brown, N. F., Ng, S. M., Brooks, C., Coutts, T., Holmes, J., Roberts, C., . . . Mulholland, P. (2020). A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.. BMC cancer, 20(1), 198. doi:10.1186/s12885-020-6624-y
TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.
Fielden, J., Wiseman, K., Torrecilla, I., Li, S., Hume, S., Chiang, S. -C., . . . Ramadan, K. (2020). TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts.. Nature communications, 11(1), 1274. doi:10.1038/s41467-020-15000-w
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., . . . New EPOC investigators. (2020). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.. The Lancet. Oncology, 21(3), 398-411. doi:10.1016/s1470-2045(19)30798-3
Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.
Mukherjee, S., Hurt, C., Cox, C., Radhakrishna, G., Gwynne, S., Bateman, A. R., . . . Crosby, T. D. L. (2020). Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.. Journal of Clinical Oncology, 38(4_suppl), 373. doi:10.1200/jco.2020.38.4_suppl.373
Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.
Yin, J., Cohen, R., Jin, Z., Liu, H., Pederson, L., Adams, R., . . . Lenz, H. -J. (2020). Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. Journal of Clinical Oncology, 38(4_suppl), 188. doi:10.1200/jco.2020.38.4_suppl.188
Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC).
Mukherjee, S., Lanfredini, S., Cox, C., Thapa, A., Hughes, S., Bangs, F., . . . O'Neill, E. (2020). Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 38(4_suppl), 740. doi:10.1200/jco.2020.38.4_suppl.740
A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality.
Jones, D. A., Smith, J., Mei, X. W., Hawkins, M. A., Maughan, T., van den Heuvel, F., . . . Gray, A. (2020). A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality.. Clinical and translational radiation oncology, 20, 19-26. doi:10.1016/j.ctro.2019.10.007
Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
Summers, M. G., Maughan, T. S., Kaplan, R., Law, P. J., Houlston, R. S., Escott-Price, V., & Cheadle, J. P. (2020). Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.. European journal of cancer (Oxford, England : 1990), 124, 56-63. doi:10.1016/j.ejca.2019.09.024
Modifiable pathways for colorectal cancer: a mendelian randomisation analysis.
Cornish, A. J., Law, P. J., Timofeeva, M., Palin, K., Farrington, S. M., Palles, C., . . . Houlston, R. S. (2020). Modifiable pathways for colorectal cancer: a mendelian randomisation analysis.. The lancet. Gastroenterology & hepatology, 5(1), 55-62. doi:10.1016/s2468-1253(19)30294-8
2019
Abstract B40: High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial
Willenbrock, F., Cox, C., Wilhelm-Benartzi, C., Abraham, A., Owens, R., Sabbagh, A., . . . Mukherjee, S. (2019). Abstract B40: High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial. Cancer Research, 79(24_Supplement), B40. doi:10.1158/1538-7445.panca19-b40
Abstract PR02: Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes
Eyres, M., Lanfredini, S., Willenbrock, F., Thapa, A., Blake, A., Burns, A., . . . O'Neill, E. (2019). Abstract PR02: Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes. Cancer Research, 79(24_Supplement), PR02. doi:10.1158/1538-7445.panca19-pr02
Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression and drug response
The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression.
Thomas, R., Trapani, D., Goodyer-Sait, L., Tomkova, M., Fernandez-Rozadilla, C., Sahnane, N., . . . Lewis, A. (2019). The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression.. Scientific reports, 9(1), 13463. doi:10.1038/s41598-019-49952-x
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.
Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., . . . Aide et Recherche en Cancerologie Digestive Group. (2019). Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.. JAMA network open, 2(9), e1911750. doi:10.1001/jamanetworkopen.2019.11750
NRF2 Metagene Expression Associated with Worse Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
O'Cathail, S. M., Chieh, W. H., Maughan, T. S., & Hawkins, M. A. (2019). NRF2 Metagene Expression Associated with Worse Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics, 105(1), S160. doi:10.1016/j.ijrobp.2019.06.177
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Gray, V., Briggs, S., Palles, C., Jaeger, E., Iveson, T., Kerr, R., . . . Church, D. N. (2019). Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.. Journal of the National Cancer Institute, 111(8), 828-836. doi:10.1093/jnci/djy215
A metagene of NRF2 expression is a prognostic biomarker in all stage colorectal cancer
Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer
Domingo, E., Chatzipli, A., Richman, S., Blake, A., Hardy, C., Whalley, C., . . . Koelzer, V. H. (2019). Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer. Cancer Research, 79(13_Supplement), 4446. doi:10.1158/1538-7445.am2019-4446
Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer
Domingo, E., Chatzipli, A., Richman, S., Blake, A., Hardy, C., Whalley, C., . . . Koelzer, V. H. (2019). Abstract 4446: Assessment of tissue composition with digital pathology in colorectal cancer. In Bioinformatics, Convergence Science, and Systems Biology (pp. 4446). American Association for Cancer Research. doi:10.1158/1538-7445.sabcs18-4446
CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial
Willenbrock, F., Cox, C., Wilhelm-benartzic, C., Owens, R., Sabbagh, A., Abraham, A., . . . Mukherjee, S. (2019). CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial. Annals of Oncology, 30, iv110. doi:10.1093/annonc/mdz156.001
Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Hague, D., Townsend, S., Masters, L., Rauchenberger, M., Van Looy, N., Diaz-Montana, C., . . . STAMPEDE and FOCUS4 investigators. (2019). Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.. Trials, 20(1), 294. doi:10.1186/s13063-019-3322-7
Mind the gap? The platform trial as a working environment.
Morrell, L., Hordern, J., Brown, L., Sydes, M. R., Amos, C. L., Kaplan, R. S., . . . Maughan, T. S. (2019). Mind the gap? The platform trial as a working environment.. Trials, 20(1), 297. doi:10.1186/s13063-019-3377-5
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Schiavone, F., Bathia, R., Letchemanan, K., Masters, L., Amos, C., Bara, A., . . . past and present members of the STAMPEDE and FOCUS4 Trial Management Group. (2019). This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.. Trials, 20(1), 264. doi:10.1186/s13063-019-3216-8
Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning
Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.
Henderson, R., French, D., Sullivan, R., Maughan, T., Clarke, M., & Lawler, M. (2019). Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.. Oncotarget, 10(36), 3408-3423. doi:10.18632/oncotarget.26909
Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.
Margalit, O., Harmsen, W. S., shacham-Shmueli, E., Petersen, M., Boursi, B., Saltz, L. B., . . . Lenz, H. -J. (2019). Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 37(15_suppl), 3539. doi:10.1200/jco.2019.37.15_suppl.3539
Association analyses identify 31 new risk loci for colorectal cancer susceptibility
Law, P. J., Timofeeva, M., Fernandez-Rozadilla, C., Timofeeva, A., Broderick, P., Studd, J., . . . Thibodeau, S. N. (2019). Association analyses identify 31 new risk loci for colorectal cancer susceptibility. NATURE COMMUNICATIONS, 10. doi:10.1038/s41467-019-09775-w
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
McGowan, D. R., Skwarski, M., Bradley, K. M., Campo, L., Fenwick, J. D., Gleeson, F. V., . . . Higgins, G. S. (2019). Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. EUROPEAN JOURNAL OF CANCER, 113, 87-95. doi:10.1016/j.ejca.2019.03.015
Guidelines for using sigQC for systematic evaluation of gene signatures.
Dhawan, A., Barberis, A., Cheng, W. -C., Domingo, E., West, C., Maughan, T., . . . Buffa, F. M. (2019). Guidelines for using sigQC for systematic evaluation of gene signatures.. Nature protocols, 14(5), 1377-1400. doi:10.1038/s41596-019-0136-8
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Strauss, V. Y., Shaw, R., Virdee, P. S., Hurt, C. N., Ward, E., Tranter, B., . . . Mukherjee, S. (2019). Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).. BMC cancer, 19(1), 121. doi:10.1186/s12885-019-5307-z
Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).
O'Cathail, S. M., Wu, C. -H., Lewis, A., Maughan, T., & Hawkins, M. A. (2019). Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).. Journal of Clinical Oncology, 37(4_suppl), 557. doi:10.1200/jco.2019.37.4_suppl.557
2018
Are All Colorectal Oligometastases Equal?
O'Cathail, S. M., Owens, R., Maughan, T. S., & Hawkins, M. A. (2018). Are All Colorectal Oligometastases Equal?. International Journal of Radiation Oncology*Biology*Physics, 102(3), e14. doi:10.1016/j.ijrobp.2018.07.224
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.
Salem, M. E., Yin, J., Weinberg, B. A., Renfro, L. A., Pederson, L. D., Maughan, T. S., . . . Marshall, J. L. (2018). Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.. European journal of cancer (Oxford, England : 1990), 103, 205-213. doi:10.1016/j.ejca.2018.08.020
KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer
O'Cathail, S. M., Lewis, A., Hawkins, M. A., & Maughan, T. S. (2018). KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics, 102(3), e191-e192. doi:10.1016/j.ijrobp.2018.07.693
Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Maynard, J., . . . Cheadle, J. P. (2018). Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Annals of Oncology, 29, viii22. doi:10.1093/annonc/mdy269.072
Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.
Kannan, P., Kretzschmar, W. W., Winter, H., Warren, D., Bates, R., Allen, P. D., . . . Kersemans, V. (2018). Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(19), 4694-4704. doi:10.1158/1078-0432.ccr-18-0033
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Maynard, J., . . . Cheadle, J. P. (2018). Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. EUROPEAN JOURNAL OF CANCER, 102, 31-39. doi:10.1016/j.ejca.2018.07.009
SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component
Mukherjee, S., Virdee, P., Shaw, R., Bridgewater, J., Radhakrishna, G., Falk, S., . . . Maughan, T. S. (2018). SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component. Annals of Oncology, 29, viii243. doi:10.1093/annonc/mdy282.103
Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study
Skwarski, M., Mcgowan, D., Bradley, K., Fenwick, J., Gleeson, F., Horne, A., . . . Higgins, G. (2018). Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study. In JOURNAL OF THORACIC ONCOLOGY Vol. 13 (pp. S594). doi:10.1016/j.jtho.2018.08.888
The evolutionary landscape of colorectal tumorigenesis.
Cross, W., Kovac, M., Mustonen, V., Temko, D., Davis, H., Baker, A. -M., . . . Tomlinson, I. P. M. (2018). The evolutionary landscape of colorectal tumorigenesis.. Nature ecology & evolution, 2(10), 1661-1672. doi:10.1038/s41559-018-0642-z
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.
Gollins, S., West, N., Sebag-Montefiore, D., Susnerwala, S., Falk, S., Brown, N., . . . Hurt, C. (2018). A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.. British journal of cancer, 119(6), 697-706. doi:10.1038/s41416-018-0209-4
Abstract 5175: Advancing the molecular understanding of stage I colorectal cancer
Dunne, P., Loughrey, M. B., Coleman, H. G., McBride, R., Campbell, J., Alderdice, M., . . . consortium, S. C. (2018). Abstract 5175: Advancing the molecular understanding of stage I colorectal cancer. Cancer Research, 78(13_Supplement), 5175. doi:10.1158/1538-7445.am2018-5175
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies
Alderdice, M., Richman, S. D., Gollins, S., Stewart, P., Hurt, C., Adams, R., . . . Dunne, P. D. (2018). Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-5365
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.
Sjoquist, K. M., Renfro, L. A., Simes, R. J., Tebbutt, N. C., Clarke, S., Seymour, M. T., . . . Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD). (2018). Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.. Journal of the National Cancer Institute, 110(6), 638-648. doi:10.1093/jnci/djx253
Surgical quality and the impact of liver resection on outcome in the New EPOC study.
Pugh, S. A., Bridgewater, J. A., Garden, O. J., Cunningham, D., Maughan, T., Maishman, T., . . . Primrose, J. N. (2018). Surgical quality and the impact of liver resection on outcome in the New EPOC study.. Journal of Clinical Oncology, 36(15_suppl), 3559. doi:10.1200/jco.2018.36.15_suppl.3559
Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies
Alderdice, M., Richman, S. D., Gollins, S., Stewart, J. P., Hurt, C., Adams, R., . . . Dunne, P. D. (2018). Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. JOURNAL OF PATHOLOGY, 245(1), 19-28. doi:10.1002/path.5051
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
Sobrero, A., Grothey, A., Iveson, T., Labianca, R., Yoshino, T., Taieb, J., . . . Cervantes, A. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of oncology : official journal of the European Society for Medical Oncology, 29(5), 1099-1107. doi:10.1093/annonc/mdy064
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., . . . FOCUS4 Trial Investigators. (2018). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.. The lancet. Gastroenterology & hepatology, 3(3), 162-171. doi:10.1016/s2468-1253(17)30394-1
Patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies may inform prospective clinical trials
Alderdice, M., McCorry, A., Isella, C., McArt, D., Richman, S., Morton, D., . . . Dunne, P. (2018). Patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies may inform prospective clinical trials. European Journal of Surgical Oncology, 44, S49. doi:10.1016/j.ejso.2018.01.017
Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.
Ferraro, D. A., Zalcberg, J. R., Shi, Q., Meyers, J. P., Seymour, M. T., Saltz, L., . . . Adams, R. (2018). Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.. Journal of Clinical Oncology, 36(4_suppl), 617. doi:10.1200/jco.2018.36.4_suppl.617
Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
Tanskanen, T., van den Berg, L., Välimäki, N., Aavikko, M., Ness-Jensen, E., Hveem, K., . . . Aaltonen, L. A. (2018). Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.. International journal of cancer, 142(3), 540-546. doi:10.1002/ijc.31076
Advanced Radiotherapy Technologies Network in the UK (ART-NET) – focus on lung cancer
Brown, S., Van Herk, M., Chuter, R., Falk, S., Kirkby, K., Mackay, R., . . . Faivre-Finn, C. (2018). Advanced Radiotherapy Technologies Network in the UK (ART-NET) – focus on lung cancer. Lung Cancer, 115, S60. doi:10.1016/s0169-5002(18)30166-1
Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.
West, H., Coffey, M., Wagner, M. J., McLeod, H. L., Colley, J. P., Adams, R. A., . . . Cheadle, J. P. (2018). Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.. JCO precision oncology, 2, 1-18. doi:10.1200/po.18.00090
2017
Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).
Harrington, K., Hall, E., Hawkins, M., Henry, A., MacKay, R., Maughan, T., . . . ART-NET Steering Committee. (2017). Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).. Clinical oncology (Royal College of Radiologists (Great Britain)), 29(11), 707-710. doi:10.1016/j.clon.2017.07.016
The 'molecularly unstratified' patient: a focus for moral, psycho-social and societal research.
Hordern, J., Maughan, T., Feiler, T., Morrell, L., Horne, R., & Sullivan, R. (2017). The 'molecularly unstratified' patient: a focus for moral, psycho-social and societal research.. Biomedicine hub, 2(Suppl 1), 480422. doi:10.1159/000480422
<i>sigQC</i>: A procedural approach for standardising the evaluation of gene signatures
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis
May-Wilson, S., Sud, A., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2017). Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. EUROPEAN JOURNAL OF CANCER, 84, 228-238. doi:10.1016/j.ejca.2017.07.034
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
Parmar, M. K., Sydes, M. R., Cafferty, F. H., Choodari-Oskooei, B., Langley, R. E., Brown, L., . . . Royston, P. J. (2017). Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.. In Clinical trials (London, England) Vol. 14 (pp. 451-461). doi:10.1177/1740774517725697
[<sup>18</sup>F]Fluoromisonidazole PET in rectal cancer.
Puri, T., Greenhalgh, T. A., Wilson, J. M., Franklin, J., Wang, L. M., Strauss, V., . . . Maughan, T. (2017). [<sup>18</sup>F]Fluoromisonidazole PET in rectal cancer.. EJNMMI research, 7(1), 78. doi:10.1186/s13550-017-0324-x
How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
Bonnetain, F., Borg, C., Adams, R. R., Ajani, J. A., Benson, A., Bleiberg, H., . . . de Gramont, A. (2017). How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.. Annals of oncology : official journal of the European Society for Medical Oncology, 28(9), 2077-2085. doi:10.1093/annonc/mdx191
Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial
Bridgewater, J., Pugh, S., Whitehead, A., Stanton, L., Eminton, Z., Mellor, J., . . . Primrose, J. (2017). Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. Annals of Oncology, 28, v162. doi:10.1093/annonc/mdx393.010
Surgical quality and the impact of liver resection on outcome in the new EPOC study
Pugh, S., Bridgewater, J., Finch-Jones, M., Rees, M., O'Reilly, D., Peterson, M., . . . Primrose, J. (2017). Surgical quality and the impact of liver resection on outcome in the new EPOC study. Annals of Oncology, 28, v167-v168. doi:10.1093/annonc/mdx393.020
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.
Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Tejpar, S., . . . Cheadle, J. P. (2017). Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.. Journal of medical genetics, 54(8), 567-571. doi:10.1136/jmedgenet-2016-104317
Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables.
Stewart, J. P., Richman, S., Maughan, T., Lawler, M., Dunne, P. D., & Salto-Tellez, M. (2017). Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables.. Biochimica et biophysica acta. Reviews on cancer, 1868(1), 258-272. doi:10.1016/j.bbcan.2017.05.005
Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.
O'Cathail, S. M., Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W., & Hawkins, M. A. (2017). Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.. Frontiers in oncology, 7, 153. doi:10.3389/fonc.2017.00153
Abstract LB-042: Cancer cell intrinsic gene expression signatures minimize the confounding effects of intratumoral heterogeneity in colorectal cancer patient classification
Dunne, P. D., O'Reilly, P., Roddy, A., Alderdice, M., Richman, S., Maughan, T., . . . Lawler, M. (2017). Abstract LB-042: Cancer cell intrinsic gene expression signatures minimize the confounding effects of intratumoral heterogeneity in colorectal cancer patient classification. Cancer Research, 77(13_Supplement). doi:10.1158/1538-7445.am2017-lb-042
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
Rodriguez-Broadbent, H., Law, P. J., Sud, A., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2017). Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 140(12), 2701-2708. doi:10.1002/ijc.30709
Depletion of signal recognition particle 72kDa increases radiosensitivity.
Prevo, R., Tiwana, G. S., Maughan, T. S., Buffa, F. M., McKenna, W. G., & Higgins, G. S. (2017). Depletion of signal recognition particle 72kDa increases radiosensitivity.. Cancer biology & therapy, 18(6), 425-432. doi:10.1080/15384047.2017.1323587
<i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.
Summers, M. G., Smith, C. G., Maughan, T. S., Kaplan, R., Escott-Price, V., & Cheadle, J. P. (2017). <i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(11), 2742-2749. doi:10.1158/1078-0432.ccr-16-1541
SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
Virdee, P., Shaw, R., Strauss, V., Hamill, C., Hurt, C., Gwynne, S., . . . Mukherjee, S. (2017). SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer. Annals of Oncology, 28, iii82-iii83. doi:10.1093/annonc/mdx261.231
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., . . . Lawler, M. (2017). Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification.. Nature communications, 8, 15657. doi:10.1038/ncomms15657
An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (?plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC).
Adams, R., Goey, K., Chibaudel, B., Koopman, M., Punt, C. J. A., Arnold, D., . . . Fisher, D. (2017). An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (?plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 35(15_suppl), e15044. doi:10.1200/jco.2017.35.15_suppl.e15044
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.
Hurt, C. N., Falk, S., Crosby, T., McDonald, A., Ray, R., Joseph, G., . . . Mukherjee, S. (2017). Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.. British journal of cancer, 116(10), 1264-1270. doi:10.1038/bjc.2017.95
EP-1278: FMISO-PET & perfusion CT at baseline and; week 2 CRT as predictive markers for response in rectal ca
Greenhalgh, T., Wilson, J., Puri, T., Franklin, J., Wang, L., Goldin, R., . . . Maughan, T. (2017). EP-1278: FMISO-PET & perfusion CT at baseline and; week 2 CRT as predictive markers for response in rectal ca. Radiotherapy and Oncology, 123, S686-S687. doi:10.1016/s0167-8140(17)31713-9
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Staffurth, J., Ray, R., . . . Mukherjee, S. (2017). Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.. British journal of cancer, 116(6), 709-716. doi:10.1038/bjc.2017.21
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Wood, G., Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., . . . Bridgewater, J. (2017). Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.. Anti-cancer drugs, 28(5), 546-550. doi:10.1097/cad.0000000000000488
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Seligmann, J. F., Fisher, D., Smith, C. G., Richman, S. D., Elliott, F., Brown, S., . . . Middleton, G. (2017). Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.. Annals of oncology : official journal of the European Society for Medical Oncology, 28(3), 562-568. doi:10.1093/annonc/mdw645
NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.
Mukherjee, S., Hurt, C. N., Gwynne, S., Sebag-Montefiore, D., Radhakrishna, G., Gollins, S., . . . Crosby, T. (2017). NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.. European journal of cancer (Oxford, England : 1990), 74, 38-46. doi:10.1016/j.ejca.2016.11.031
Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database.
Salem, M. E., Yin, J., Renfro, L. A., Weinberg, B. A., Maughan, T., Adams, R., . . . Sargent, D. J. (2017). Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database.. Journal of Clinical Oncology, 35(4_suppl), 675. doi:10.1200/jco.2017.35.4_suppl.675
From Rosalind Franklin to Barack Obama: Data Sharing Challenges and Solutions in Genomics and Personalised Medicine.
Lawler, M., & Maughan, T. (2017). From Rosalind Franklin to Barack Obama: Data Sharing Challenges and Solutions in Genomics and Personalised Medicine.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 64-73. doi:10.1080/20502877.2017.1314883
Personalised Medicine: The Promise, the Hype and the Pitfalls.
Feiler, T., Gaitskell, K., Maughan, T., & Hordern, J. (2017). Personalised Medicine: The Promise, the Hype and the Pitfalls.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 1-12. doi:10.1080/20502877.2017.1314895
The Promise and the Hype of 'Personalised Medicine'.
Maughan, T. (2017). The Promise and the Hype of 'Personalised Medicine'.. The New bioethics : a multidisciplinary journal of biotechnology and the body, 23(1), 13-20. doi:10.1080/20502877.2017.1314886
2016
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Franko, J., Shi, Q., Meyers, J. P., Maughan, T. S., Adams, R. A., Seymour, M. T., . . . Analysis and Research in Cancers of the Digestive System (ARCAD) Group. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.. The Lancet. Oncology, 17(12), 1709-1719. doi:10.1016/s1470-2045(16)30500-9
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
Leszczynska, K. B., Dobrynin, G., Leslie, R. E., Ient, J., Boumelha, A. J., Senra, J. M., . . . Hammond, E. M. (2016). Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 121(2), 232-238. doi:10.1016/j.radonc.2016.10.023
FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS
Adams, R. A., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., . . . Maughan, T. (2016). FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. Annals of Oncology, 27, vi168. doi:10.1093/annonc/mdw370.57
MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
Wilson, R., Middleton, M. R., Houlden, J., Van Schaeybroeck, S., Rolfo, C. D., Elez, E., . . . Di Nicolantonio, F. (2016). MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. Annals of Oncology, 27, vi158. doi:10.1093/annonc/mdw370.28
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Weber, A. M., Drobnitzky, N., Devery, A. M., Bokobza, S. M., Adams, R. A., Maughan, T. S., & Ryan, A. J. (2016). Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.. Oncotarget, 7(38), 60807-60822. doi:10.18632/oncotarget.11845
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Pugh, S. A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J. W., . . . Primrose, J. N. (2016). Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.. British journal of cancer, 115(4), 420-424. doi:10.1038/bjc.2016.208
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., . . . Arnold, D. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 27(8), 1386-1422. doi:10.1093/annonc/mdw235
Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation
Maxwell, P., Del Favero, J., Fuchs, M. -A., Tabernero, J., Maughan, T., Middleton, M., . . . Salto Tellez, M. (2016). Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation. Cancer Research, 76(14_Supplement), 1396. doi:10.1158/1538-7445.am2016-1396
Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.
Jarvis, D., Mitchell, J. S., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., . . . Houlston, R. S. (2016). Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.. British journal of cancer, 115(2), 266-272. doi:10.1038/bjc.2016.188
O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)
Hurt, C., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., . . . Mukherjee, S. (2016). O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Annals of Oncology, 27, ii118. doi:10.1093/annonc/mdw198.03
Powering the Smart City
Maughan, T. (2016). Powering the Smart City. Engineering & Technology, 11(5), 26-29. doi:10.1049/et.2016.0500
SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (± nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
Mukherjee, S., Virdee, P., Love, S., Ward, E., Hamill, C., Hurt, C. N., . . . Bridgewater, J. (2016). SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (± nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer. Pancreatology, 16(3), S3-S4. doi:10.1016/j.pan.2016.04.016
Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.
Orlando, G., Law, P. J., Palin, K., Tuupanen, S., Gylfe, A., Hänninen, U. A., . . . Houlston, R. S. (2016). Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.. Human molecular genetics, 25(11), 2349-2359. doi:10.1093/hmg/ddw087
WE‐AB‐202‐10: Modelling Individual Tumor‐Specific Control Probability for Hypoxia in Rectal Cancer
Warren, S., Warren, D. R., Wilson, J. M., Muirhead, R., Hawkins, M. A., Maughan, T., & Partridge, M. (2016). WE‐AB‐202‐10: Modelling Individual Tumor‐Specific Control Probability for Hypoxia in Rectal Cancer. Medical Physics, 43(6Part38), 3796. doi:10.1118/1.4957751
Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.
Lewin, J. H., Vis, D. J., Voest, E. E., Liao, R., Nederlof, P. M., Conley, B. A., . . . Lawler, M. (2016). Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.. Journal of Clinical Oncology, 34(15_suppl), 11502. doi:10.1200/jco.2016.34.15_suppl.11502
Exploring outcomes of <i>RAS</i>-mutant (<i>RAS</i> mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs).
Seligmann, J. F., Fisher, D., Smith, C. G., Elliott, F., Richman, S., Quirke, P., . . . Middleton, G. W. (2016). Exploring outcomes of <i>RAS</i>-mutant (<i>RAS</i> mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs).. Journal of Clinical Oncology, 34(15_suppl), 3561. doi:10.1200/jco.2016.34.15_suppl.3561
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
Wilson, J. M., Fokas, E., Dutton, S. J., Patel, N., Hawkins, M. A., Eccles, C., . . . Brunner, T. B. (2016). ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. RADIOTHERAPY AND ONCOLOGY, 119(2), 306-311. doi:10.1016/j.radonc.2016.03.021
Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., & Bridgewater, J. (2016). Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.. British journal of cancer, 114(6), 612-615. doi:10.1038/bjc.2016.23
A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
Graham, J. S., Boyd, K., Coxon, F. Y., Wall, L. R., Eatock, M. M., Maughan, T. S., . . . Evans, T. R. J. (2016). A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.. BMC research notes, 9, 161. doi:10.1186/s13104-015-1778-4
Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.
Mukherjee, S., Hurt, C., Falk, S., Gollins, S., Staffurth, J., Ray, R., . . . Crosby, T. D. L. (2016). Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.. Journal of Clinical Oncology, 34(4_suppl), 118. doi:10.1200/jco.2016.34.4_suppl.118
Molecular Taxonomy and Tumourigenesis of Colorectal Cancer.
Biswas, S., Holyoake, D., & Maughan, T. S. (2016). Molecular Taxonomy and Tumourigenesis of Colorectal Cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 28(2), 73-82. doi:10.1016/j.clon.2015.11.001
NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.
Mukherjee, S., Hurt, C., Gwynne, S., Bateman, A., Gollins, S., Radhakrishna, G., . . . Crosby, T. D. L. (2016). NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. Journal of Clinical Oncology, 34(4_suppl), 3. doi:10.1200/jco.2016.34.4_suppl.3
Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.
Franko, J., Shi, Q., Meyers, J. P., Heinemann, V., Falcone, A., Tebbutt, N. C., . . . Grothey, A. (2016). Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database.. Journal of Clinical Oncology, 34(4_suppl), 656. doi:10.1200/jco.2016.34.4_suppl.656
Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.
Phipps, A. I., Passarelli, M. N., Chan, A. T., Harrison, T. A., Jeon, J., Hutter, C. M., . . . Newcomb, P. A. (2016). Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.. Carcinogenesis, 37(1), 87-95. doi:10.1093/carcin/bgv161
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.
Richman, S. D., Adams, R., Quirke, P., Butler, R., Hemmings, G., Chambers, P., . . . FOCUS4 Trial Management Group. (2016). Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.. Journal of clinical pathology, 69(1), 35-41. doi:10.1136/jclinpath-2015-203097
2015
Is farming the future of cities?
EdwardsMaughan, C. (2015). Is farming the future of cities?. Engineering & Technology, 10(12), 56-59. doi:10.1049/et.2016.1206
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Hurt, C. N., Mukherjee, S., Bridgewater, J., Falk, S., Crosby, T., McDonald, A., . . . Johnson, C. (2015). Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.. International journal of radiation oncology, biology, physics, 93(4), 810-818. doi:10.1016/j.ijrobp.2015.08.026
2104 Derived neutrophil to lymphocyte ratio is not predictive for use of a continuous or intermittent first-line oxaliplatin/fluoropyrimidine combination in patients with advanced colorectal cancer: A post-hoc analysis of the MRC COIN study
Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., & Bridgewater, J. (2015). 2104 Derived neutrophil to lymphocyte ratio is not predictive for use of a continuous or intermittent first-line oxaliplatin/fluoropyrimidine combination in patients with advanced colorectal cancer: A post-hoc analysis of the MRC COIN study. European Journal of Cancer, 51, S363-S364. doi:10.1016/s0959-8049(16)31026-7
Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.
Rees, J., Hurt, C. N., Gollins, S., Mukherjee, S., Maughan, T., Falk, S. J., . . . Crosby, T. (2015). Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.. British journal of cancer, 113(4), 603-610. doi:10.1038/bjc.2015.258
Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.
Al-Tassan, N. A., Whiffin, N., Hosking, F. J., Palles, C., Farrington, S. M., Dobbins, S. E., . . . Houlston, R. S. (2015). Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.. Scientific reports, 5, 12372. doi:10.1038/srep12372
Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.
Smith, C. G., Fisher, D., Harris, R., Maughan, T. S., Phipps, A. I., Richman, S., . . . Cheadle, J. P. (2015). Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(15), 3453-3461. doi:10.1158/1078-0432.ccr-14-3136
Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.
Lawler, M., Kaplan, R., Wilson, R. H., Maughan, T., & S-CORT Consortium. (2015). Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.. The oncologist, 20(8), 849-851. doi:10.1634/theoncologist.2015-0014
Is China's hydroelectric revolution green enough?
Maughan, T. (2015). Is China's hydroelectric revolution green enough?. Engineering & Technology, 10(7), 72-75. doi:10.1049/et.2015.0723
Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.
Primrose, J. N., Cunningham, D., Garden, O. J., Maughan, T. S., Pugh, S. A., Stanton, L., . . . Bridgewater, J. A. (2015). Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(21), 2405-2406. doi:10.1200/jco.2014.60.1344
P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism
Wilson, J., Hackett, S., Durrant, L., Dutton, S., Chu, K. -Y., Eccles, C., . . . Mukherjee, S. (2015). P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer – functional imaging is prognostic and provides proof of mechanism. Annals of Oncology, 26, iv53. doi:10.1093/annonc/mdv233.182
A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.
Al-Tassan, N. A., Whiffin, N., Hosking, F. J., Palles, C., Farrington, S. M., Dobbins, S. E., . . . Houlston, R. S. (2015). A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.. Scientific reports, 5, 10442. doi:10.1038/srep10442
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–Mechanism and clinical outcomes.
Wilson, J. M., Dutton, S. J., Hackett, S. L., Durrant, L., Chu, K. -Y., Eccles, C., . . . Mukherjee, S. (2015). ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–Mechanism and clinical outcomes.. Journal of Clinical Oncology, 33(15_suppl), e15279. doi:10.1200/jco.2015.33.15_suppl.e15279
Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.
Pugh, S. A., Bridgewater, J. A., Moutasim, K., Thomas, G., Laurent-Puig, P., Thiébaut, R., . . . Primrose, J. N. (2015). Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. Journal of Clinical Oncology, 33(15_suppl), 3545. doi:10.1200/jco.2015.33.15_suppl.3545
Exploring the poor outcomes of <i>BRAF </i>mutant (<i>BRAF</i> mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs).
Seligmann, J. F., Fisher, D., Elliott, F., Richman, S., Butler, R., Cheadle, J., . . . Middleton, G. W. (2015). Exploring the poor outcomes of <i>BRAF </i>mutant (<i>BRAF</i> mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs).. Journal of Clinical Oncology, 33(15_suppl), 3509. doi:10.1200/jco.2015.33.15_suppl.3509
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in <i>RAS</i>MT and <i>RAS</i>WT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Van Schaeybroeck, S., Rolfo, C. D., Élez, E., Kelly, S., Houlden, J., Collins, L., . . . Middleton, M. R. (2015). MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in <i>RAS</i>MT and <i>RAS</i>WT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 33(15_suppl), TPS3632. doi:10.1200/jco.2015.33.15_suppl.tps3632
Use of FLIM histology-based HER2-HER3 heterodimer quantification and a Bayesian latent class proportional hazards model to predict cetuximab response in the COIN and new EPOC trials.
Ng, T., Weitsman, G., Barber, P., Lawler, K., Rowley, M., Elshtein, G., . . . Coolen, A. (2015). Use of FLIM histology-based HER2-HER3 heterodimer quantification and a Bayesian latent class proportional hazards model to predict cetuximab response in the COIN and new EPOC trials.. Journal of Clinical Oncology, 33(15_suppl), e14535. doi:10.1200/jco.2015.33.15_suppl.e14535
NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
Mukherjee, S., Hurt, C. N., Gwynne, S., Bateman, A., Gollins, S., Radhakrishna, G., . . . Crosby, T. (2015). NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.. BMC cancer, 15, 48. doi:10.1186/s12885-015-1062-y
Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.
Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Zalcberg, J. R., Maughan, T., . . . Buyse, M. E. (2015). Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. Journal of Clinical Oncology, 33(3_suppl), 666. doi:10.1200/jco.2015.33.3_suppl.666
Correlating Tumour Histology and ex vivo MRI Using Dense Modality-Independent Patch-Based Descriptors
Hallack, A., Papież, B. W., Wilson, J., Wang, L. M., Maughan, T., Gooding, M. J., & Schnabel, J. A. (2015). Correlating Tumour Histology and ex vivo MRI Using Dense Modality-Independent Patch-Based Descriptors. In Unknown Conference (pp. 137-145). Springer International Publishing. doi:10.1007/978-3-319-28194-0_17
2014
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., . . . Koopman, M. (2014). Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(20), 5322-5330. doi:10.1158/1078-0432.ccr-14-0332
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
Lieu, C. H., Renfro, L. A., de Gramont, A., Meyers, J. P., Maughan, T. S., Seymour, M. T., . . . Aide et Recherche en Cancérologie Digestive Foundation. (2014). Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(27), 2975-2984. doi:10.1200/jco.2013.54.9329
Analysis of Progression Free Survival in the New Epoc Study in an All Ras Wild-Type Population
Bridgewater, J. A., Pugh, S. A., Moutasim, K., Thomas, G. J., Thiébaut, R., Liebaert, F., . . . Primrose, J. N. (2014). Analysis of Progression Free Survival in the New Epoc Study in an All Ras Wild-Type Population. Annals of Oncology, 25, iv185. doi:10.1093/annonc/mdu333.44
Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
Bridgewater, J. A., Pugh, S. A., Moutasim, K., Thomas, G., Thiébaut, R., Liebaert, F., . . . Primrose, J. N. (2014). Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.. Journal of Clinical Oncology, 32(15_suppl), 3566. doi:10.1200/jco.2014.32.15_suppl.3566
Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.
Sommeijer, D. W., Shi, Q., Saad, E. D., Coart, E., Buyse, M. E., Burzykowski, T., . . . Zalcberg, J. R. (2014). Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. Journal of Clinical Oncology, 32(15_suppl), 3538. doi:10.1200/jco.2014.32.15_suppl.3538
Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-relatedquality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.
Mukherjee, S., Hurt, C., Dutton, P., Bridgewater, J. A., Crosby, T., Mcdonald, A., . . . Griffiths, G. (2014). Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-relatedquality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.. Journal of Clinical Oncology, 32(15_suppl), 4126. doi:10.1200/jco.2014.32.15_suppl.4126
NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.
Crosby, T., Mukherjee, S., Hurt, C., Gwynne, S., Gollins, S., Bateman, A. R., . . . Griffiths, G. (2014). NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.. Journal of Clinical Oncology, 32(15_suppl), TPS4144. doi:10.1200/jco.2014.32.15_suppl.tps4144
Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.
Pugh, S. A., Ball, A., Bowers, M., Falk, S., Finch-Jones, M., Valle, J. W., . . . Primrose, J. N. (2014). Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. Journal of Clinical Oncology, 32(15_suppl), 3556. doi:10.1200/jco.2014.32.15_suppl.3556
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
Maughan, T. S., Meade, A. M., Adams, R. A., Richman, S. D., Butler, R., Fisher, D., . . . Kaplan, R. (2014). A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. British journal of cancer, 110(9), 2178-2186. doi:10.1038/bjc.2014.182
Response.
Smith, C. G., West, H., Harris, R., Idziaszczyk, S., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2014). Response.. Journal of the National Cancer Institute, 106(5), dju087. doi:10.1093/jnci/dju087
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
Becerra, C. R., Salazar, R., Garcia-Carbonero, R., Thomas, A. L., Vázquez-Mazón, F. J., Cassidy, J., . . . Bergsland, E. K. (2014). Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.. Cancer chemotherapy and pharmacology, 73(4), 695-702. doi:10.1007/s00280-014-2391-2
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Wasan, H., Meade, A. M., Adams, R., Wilson, R., Pugh, C., Fisher, D., . . . COIN-B investigators. (2014). Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.. The Lancet. Oncology, 15(6), 631-639. doi:10.1016/s1470-2045(14)70106-8
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., . . . Bridgewater, J. (2014). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.. The Lancet. Oncology, 15(6), 601-611. doi:10.1016/s1470-2045(14)70105-6
2013
Evaluating many treatments and biomarkers in oncology: a new design.
Kaplan, R., Maughan, T., Crook, A., Fisher, D., Wilson, R., Brown, L., & Parmar, M. (2013). Evaluating many treatments and biomarkers in oncology: a new design.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(36), 4562-4568. doi:10.1200/jco.2013.50.7905
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Middleton, G., Brown, S., Lowe, C., Maughan, T., Gwyther, S., Oliver, A., . . . Seymour, M. (2013). A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).. European journal of cancer (Oxford, England : 1990), 49(16), 3507-3516. doi:10.1016/j.ejca.2013.06.017
Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.
Smith, C. G., West, H., Harris, R., Idziaszczyk, S., Maughan, T. S., Kaplan, R., . . . Cheadle, J. P. (2013). Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.. Journal of the National Cancer Institute, 105(16), 1249-1253. doi:10.1093/jnci/djt183
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
Smith, C. G., Fisher, D., Claes, B., Maughan, T. S., Idziaszczyk, S., Peuteman, G., . . . Cheadle, J. P. (2013). Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(15), 4104-4113. doi:10.1158/1078-0432.ccr-12-2581
Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.
Smith, C. G., Naven, M., Harris, R., Colley, J., West, H., Li, N., . . . Cheadle, J. P. (2013). Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.. Human mutation, 34(7), 1026-1034. doi:10.1002/humu.22333
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., . . . Quirke, P. (2013). Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.. The Lancet. Oncology, 14(8), 749-759. doi:10.1016/s1470-2045(13)70163-3
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., . . . Griffiths, G. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.. The Lancet. Oncology, 14(7), 627-637. doi:10.1016/s1470-2045(13)70136-0
A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.
Primrose, J. N., Falk, S., Finch-Jones, M., Valle, J. W., Sherlock, D., Hornbuckle, J., . . . Bridgewater, J. A. (2013). A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.. Journal of Clinical Oncology, 31(15_suppl), 3504. doi:10.1200/jco.2013.31.15_suppl.3504
Comprehensive pharmacogenetic profiling of advanced colorectal cancer.
Madi, A., Fisher, D., Maughan, T., Colley, J., Meade, A. M., Maynard, J., . . . Cheadle, J. (2013). Comprehensive pharmacogenetic profiling of advanced colorectal cancer.. Journal of Clinical Oncology, 31(15_suppl), 3509. doi:10.1200/jco.2013.31.15_suppl.3509
FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC).
Shiu, K. -K., Maughan, T., Wilson, R. H., Adams, R. A., Pugh, C., Brown, L., . . . Kaplan, R. S. (2013). FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC).. Journal of Clinical Oncology, 31(15_suppl), TPS3645. doi:10.1200/jco.2013.31.15_suppl.tps3645
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., . . . Sebag-Montefiore, D. (2013). Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.. The Lancet. Oncology, 14(6), 516-524. doi:10.1016/s1470-2045(13)70086-x
Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
Powell, J. R., Dojcinov, S., King, L., Wosniak, S., Gerry, S., Casbard, A., . . . Maughan, T. (2013). Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.. Leukemia & lymphoma, 54(5), 959-966. doi:10.3109/10428194.2012.733875
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., . . . Maughan, T. (2013). Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.. The Lancet. Oncology, 14(4), 317-326. doi:10.1016/s1470-2045(13)70021-4
SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC).
Mukherjee, S., Hurt, C., Griffiths, G., Bridgewater, J. A., Crosby, T., Falk, S., . . . Maughan, T. (2013). SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC).. Journal of Clinical Oncology, 31(4_suppl), LBA146. doi:10.1200/jco.2013.31.4_suppl.lba146
SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab.
Crosby, T., Hurt, C., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., . . . Griffiths, G. (2013). SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab.. Journal of Clinical Oncology, 31(4_suppl), LBA3. doi:10.1200/jco.2013.31.4_suppl.lba3
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.
Türbachova, I., Schwachula, T., Vasconcelos, I., Mustea, A., Baldinger, T., Jones, K. A., . . . Olek, S. (2013). The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.. Epigenetics, 8(11), 1226-1235. doi:10.4161/epi.26334
2012
Methodological considerations in the evaluation of radiotherapy technologies.
Burnet, N. G., Billingham, L. J., Chan, C. S. K., Hall, E., Macdougall, J., Mackay, R. I., . . . National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group. (2012). Methodological considerations in the evaluation of radiotherapy technologies.. Clinical oncology (Royal College of Radiologists (Great Britain)), 24(10), 707-709. doi:10.1016/j.clon.2012.06.003
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
Adams, R. A., Fisher, D., Farragher, S., Jasani, B., Smith, C. G., James, M. D., . . . Maughan, T. (2012). Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 30(30_suppl), 32. doi:10.1200/jco.2012.30.30_suppl.32
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Vale, C. L., Tierney, J. F., Fisher, D., Adams, R. A., Kaplan, R., Maughan, T. S., . . . Meade, A. M. (2012). Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.. Cancer treatment reviews, 38(6), 618-625. doi:10.1016/j.ctrv.2011.11.002
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.
MacGregor, T. P., Maughan, T. S., & Sharma, R. A. (2012). Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.. Journal of clinical pathology, 65(10), 867-871. doi:10.1136/jclinpath-2012-200958
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Madi, A., Fisher, D., Wilson, R. H., Adams, R. A., Meade, A. M., Kenny, S. L., . . . COIN trial research group. (2012). Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.. British journal of cancer, 107(7), 1037-1043. doi:10.1038/bjc.2012.384
Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies
Venderbosch, S., De Haan, T., Heideman, D. A. M., Maughan, T. S., Smith, C. G., Quirke, P., . . . Koopman, M. (2012). Deficient Mismatch Repair (DMMR) and Braf Mutation (MT) Status in Patients (PTS) With Metastatic Colorectal Cancer (MCRC): A Meta-Analysis of the Cairo, CAIRO2, Coin and Focus Studies. Annals of Oncology, 23, ix179. doi:10.1016/s0923-7534(20)33156-2
SP-28: Nelfinavir and RT in Pancreatic Cancer
Brunner, T. B., Hill, E., Wilson, J., Maughan, T., Eccles, C., & McKenna, W. G. (2012). SP-28: Nelfinavir and RT in Pancreatic Cancer. Radiotherapy and Oncology, 104, 29. doi:10.1016/s0167-8140(15)34582-5
O-0016 Cetuximab Combined with Infusional 5-Fluorouracil/Folinic Acid And Oxaliplatin in Metastatic Colorectal Cancer: Pooled Analysis of Coin and Opus Study Data
Taïeb, J., Maughan, T., Bokemeyer, C., Van Cutsem, E., Brodowicz, T., Folprecht, G., . . . Tabernero, J. (2012). O-0016 Cetuximab Combined with Infusional 5-Fluorouracil/Folinic Acid And Oxaliplatin in Metastatic Colorectal Cancer: Pooled Analysis of Coin and Opus Study Data. Annals of Oncology, 23, iv11. doi:10.1016/s0923-7534(19)66480-x
Common variation near <i>CDKN1A</i>, <i>POLD3</i> and <i>SHROOM2</i> influences colorectal cancer risk
Dunlop, M. G., Dobbins, S. E., Farrington, S. M., Jones, A. M., Palles, C., Whiffin, N., . . . Houlston, R. S. (2012). Common variation near <i>CDKN1A</i>, <i>POLD3</i> and <i>SHROOM2</i> influences colorectal cancer risk. NATURE GENETICS, 44(7), 770-U197. doi:10.1038/ng.2293
Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.
Taïeb, J., Maughan, T., Bokemeyer, C., Van Cutsem, E., Brodowicz, T., Folprecht, G., . . . Tabernero, J. (2012). Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.. Journal of Clinical Oncology, 30(15_suppl), 3574. doi:10.1200/jco.2012.30.15_suppl.3574
Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).
Adams, R. A., Fisher, D., Farragher, S., Scott, A., Smith, C. G., James, M. D., . . . Maughan, T. (2012). Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 30(15_suppl), 3516. doi:10.1200/jco.2012.30.15_suppl.3516
Immune responses and association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910.
Kuttruff, S., Weinschenk, T., Schoor, O., Lindner, J., Kutscher, S., Maurer, D., . . . Walter, S. (2012). Immune responses and association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910.. Journal of Clinical Oncology, 30(15_suppl), 2522. doi:10.1200/jco.2012.30.15_suppl.2522
Overall survival (OS) of advanced colorectal cancer (aCRC) patients (pts) treated with the multipeptide vaccine IMA910: Results of a matched-pair analysis with arm C pts from COIN.
Maughan, T., Adams, R. A., Mayer-Mokler, A., Nowara, E., Torday, L., Cseh, J., . . . Mayer, F. (2012). Overall survival (OS) of advanced colorectal cancer (aCRC) patients (pts) treated with the multipeptide vaccine IMA910: Results of a matched-pair analysis with arm C pts from COIN.. Journal of Clinical Oncology, 30(15_suppl), 3530. doi:10.1200/jco.2012.30.15_suppl.3530
FOCUS 3: A study to determine the feasibility of molecular selection of therapy using <i>K</i><i>-RAS</i>, <i>B</i><i>-RAF</i>, and topo-1 in patients with advanced colorectal cancer (ACRC).
Maughan, T., Wilson, R. H., Williams, G. T., Seymour, M. T., Richman, S. D., Quirke, P., . . . Kaplan, R. S. (2012). FOCUS 3: A study to determine the feasibility of molecular selection of therapy using <i>K</i><i>-RAS</i>, <i>B</i><i>-RAF</i>, and topo-1 in patients with advanced colorectal cancer (ACRC).. Journal of Clinical Oncology, 30(4_suppl), 563. doi:10.1200/jco.2012.30.4_suppl.563
Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial.
Wasan, H., Adams, R. A., Wilson, R. H., Pugh, C., Fisher, D., Madi, A., . . . Maughan, T. (2012). Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial.. Journal of Clinical Oncology, 30(4_suppl), 536. doi:10.1200/jco.2012.30.4_suppl.536
X-ACT: an important step on an unfinished journey.
Maughan, T. (2012). X-ACT: an important step on an unfinished journey.. Annals of oncology : official journal of the European Society for Medical Oncology, 23(7), 1655-1658. doi:10.1093/annonc/mds114
2011
6006 ORAL Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
Wasan, H., Adams, R. A., Wilson, R. H., Pugh, C. A., Fisher, D., Madi, A., . . . Maughan, T. S. (2011). 6006 ORAL Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial. European Journal of Cancer, 47, S393. doi:10.1016/s0959-8049(11)71651-3
6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
Seymour, M. T., Brown, S. R., Richman, S., Middleton, G. W., Maughan, T. S., Maisey, N., . . . Quirke, P. (2011). 6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 47, S393. doi:10.1016/s0959-8049(11)71652-5
6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
Middleton, G. W., Brown, S. R., Gwyther, S. J., Maughan, T. S., Wadsley, J., Chau, I., . . . Seymour, M. T. (2011). 6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 47, S420-S421. doi:10.1016/s0959-8049(11)71742-7
The treatment of patients with low tumour burden and/or slow growing disease.
Maughan, T. S. (2011). The treatment of patients with low tumour burden and/or slow growing disease.. European journal of cancer (Oxford, England : 1990), 47 Suppl 3, S67-S75. doi:10.1016/s0959-8049(11)70149-6
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Shaw, P. H. S., Maughan, T. S., & Clarke, A. R. (2011). Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.. British journal of cancer, 105(5), 649-657. doi:10.1038/bjc.2011.291
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., . . . Illidge, T. (2011). Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.. British journal of cancer, 105(5), 628-639. doi:10.1038/bjc.2011.240
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Adams, R. A., Meade, A. M., Seymour, M. T., Wilson, R. H., Madi, A., Fisher, D., . . . MRC COIN Trial Investigators. (2011). Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.. The Lancet. Oncology, 12(7), 642-653. doi:10.1016/s1470-2045(11)70102-4
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., . . . MRC COIN Trial Investigators. (2011). Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.. Lancet (London, England), 377(9783), 2103-2114. doi:10.1016/s0140-6736(11)60613-2
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Seymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., . . . National Cancer Research Institute Colorectal Cancer Clinical Studies Group. (2011). Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.. Lancet (London, England), 377(9779), 1749-1759. doi:10.1016/s0140-6736(11)60399-1
A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.
Thomas, A. L., Wilson, R. H., Steward, W. P., Adams, R. A., Bridges, S. E., Casbard, A. C., . . . Griffiths, G. (2011). A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.. Journal of Clinical Oncology, 29(15_suppl), TPS161. doi:10.1200/jco.2011.29.15_suppl.tps161
Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
Seymour, M. T., Brown, S. R., Richman, S., Middleton, G. W., Maughan, T., Olivier, C., . . . Quirke, P. (2011). Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 29(15_suppl), 3523. doi:10.1200/jco.2011.29.15_suppl.3523
Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
Middleton, G. W., Gwyther, S. J., Brown, S. R., Maughan, T., Olivier, C., Richman, S., . . . Seymour, M. T. (2011). Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 29(15_suppl), 3566. doi:10.1200/jco.2011.29.15_suppl.3566
Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study.
Maughan, T., Wilson, R. H., Williams, G. T., Seymour, M. T., Richman, S., Quirke, P., . . . Kaplan, R. S. (2011). Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study.. Journal of Clinical Oncology, 29(15_suppl), TPS165. doi:10.1200/jco.2011.29.15_suppl.tps165
Multiplexed quantitation of growth factor receptors and pathway activation in FFPE tumor tissue from the COIN trial.
Adams, R., Hembrough, T. A., Thyparambil, S., Krizman, D., Darfler, M., Jasani, B., . . . Burrows, J. (2011). Multiplexed quantitation of growth factor receptors and pathway activation in FFPE tumor tissue from the COIN trial.. Journal of Clinical Oncology, 29(15_suppl), e14117. doi:10.1200/jco.2011.29.15_suppl.e14117
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).
Becerra, C., Salazar, R., Garcia-Carbonero, R., Thomas, A. L., Vázquez-Mazón, F., Cassidy, J., . . . Li, D. (2011). Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 29(15_suppl), 3525. doi:10.1200/jco.2011.29.15_suppl.3525
Strengthening clinical cancer research in the United Kingdom.
Stead, M., Cameron, D., Lester, N., Parmar, M., Haward, R., Kaplan, R., . . . National Cancer Research Networks across the UK. (2011). Strengthening clinical cancer research in the United Kingdom.. British journal of cancer, 104(10), 1529-1534. doi:10.1038/bjc.2011.69
Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience.
Adams, R. A., James, M. D., Smith, C. G., Wilson, R. H., Fisher, D., Kenny, S. L., . . . Jasani, B. (2011). Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience.. Journal of Clinical Oncology, 29(4_suppl), 359. doi:10.1200/jco.2011.29.4_suppl.359
Chemotherapy for older patients with colorectal cancer – Authors' reply
Seymour, M. T., Thompson, L. C., O'Mahony, S., Brewster, A. E., Wasan, H. S., & Maughan, T. S. (2011). Chemotherapy for older patients with colorectal cancer – Authors' reply. The Lancet, 378(9793), 765-766. doi:10.1016/s0140-6736(11)61369-x
Research-intensive cancer care in the NHS in the UK.
Cameron, D., Stead, M., Lester, N., Parmar, M., Haward, R., Maughan, T., . . . Selby, P. (2011). Research-intensive cancer care in the NHS in the UK.. Annals of oncology : official journal of the European Society for Medical Oncology, 22 Suppl 7, vii29-vii35. doi:10.1093/annonc/mdr423
2010
The attitudes of 1066 patients with cancer towards participation in randomised clinical trials.
Jenkins, V., Farewell, D., Batt, L., Maughan, T., Branston, L., Langridge, C., . . . Fallowfield, L. (2010). The attitudes of 1066 patients with cancer towards participation in randomised clinical trials.. British journal of cancer, 103(12), 1801-1807. doi:10.1038/sj.bjc.6606004
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.
Houlston, R. S., Cheadle, J., Dobbins, S. E., Tenesa, A., Jones, A. M., Howarth, K., . . . Tomlinson, I. P. M. (2010). Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.. Nature genetics, 42(11), 973-977. doi:10.1038/ng.670
Radiotherapy research priorities for the UK.
Maughan, T. S., Illidge, T. M., Hoskin, P., McKenna, W. G., Brunner, T. B., Stratford, I. J., . . . NCRI Clinical and Translational Radiotherapy Research Working Group. (2010). Radiotherapy research priorities for the UK.. Clinical oncology (Royal College of Radiologists (Great Britain)), 22(8), 707-709. doi:10.1016/j.clon.2010.03.006
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
Maughan, T., Adams, R., Wilson, R., Seymour, M., Meade, A., & Kaplan, R. (2010). Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(17), e275-e276. doi:10.1200/jco.2009.27.8218
A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.
Mukherjee, S., Hurt, C., Griffiths, G., Crosby, T., Staffurth, J., Bridges, S., . . . Maughan, T. S. (2010). A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.. Journal of Clinical Oncology, 28(15_suppl), TPS222. doi:10.1200/jco.2010.28.15_suppl.tps222
Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.
Maughan, T. S., Adams, R., Smith, C. G., Seymour, M. T., Wilson, R. H., Meade, A. M., . . . Kaplan, R. S. (2010). Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.. Journal of Clinical Oncology, 28(15_suppl), 3502. doi:10.1200/jco.2010.28.15_suppl.3502
Interim safety data on the ZICE trial: A randomized phase III, open-label, multicener, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases.
Barrett-Lee, P. J., Murray, N., Abraham, J., Casbard, A., Clements, H., Maughan, T. S., & Griffiths, G. (2010). Interim safety data on the ZICE trial: A randomized phase III, open-label, multicener, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases.. Journal of Clinical Oncology, 28(15_suppl), 1085. doi:10.1200/jco.2010.28.15_suppl.1085
Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.
Adams, R., Wilson, R. H., Seymour, M. T., Meade, A. M., Madi, A., Cassidy, J., . . . Maughan, T. S. (2010). Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.. Journal of Clinical Oncology, 28(15_suppl), 3525. doi:10.1200/jco.2010.28.15_suppl.3525
2009
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.
Griffiths, G. O., Burns, S., Noble, S. I., Macbeth, F. R., Cohen, D., & Maughan, T. S. (2009). FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.. BMC cancer, 9, 355. doi:10.1186/1471-2407-9-355
Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
Clements, D., Dhruva Rao, P., Ramanathan, D., Adams, R., Maughan, T. S., & Davies, M. M. (2009). Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 11(8), 845-848. doi:10.1111/j.1463-1318.2008.01695.x
15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
Adams, R., Wilson, R., Seymour, M. T., Meade, A. M., Madi, A., Cassidy, J., . . . Maughan, T. S. (2009). 15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). European Journal of Cancer Supplements, 7(3), 10. doi:10.1016/s1359-6349(09)72050-6
6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
Maughan, T., Adams, R. A., Smith, C. G., Seymour, M. T., Wilson, R., Meade, A. M., . . . Kaplan, R. (2009). 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). European Journal of Cancer Supplements, 7(3), 4-5. doi:10.1016/s1359-6349(09)72034-8
Impact of <i>K-ras</i> status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Vale, C., Tierney, J. F., Meade, A., Fisher, D., Kaplan, R., Adams, R. A., . . . Parmar, M. K. (2009). Impact of <i>K-ras</i> status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs). Journal of Clinical Oncology, 27(15_suppl), 4122. doi:10.1200/jco.2009.27.15_suppl.4122
A new opportunity for radiotherapy research in the UK.
Maughan, T. S. (2009). A new opportunity for radiotherapy research in the UK.. Clinical oncology (Royal College of Radiologists (Great Britain)), 21(3), 157-158. doi:10.1016/j.clon.2008.12.007
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Adams, R. A., Meade, A. M., Madi, A., Fisher, D., Kay, E., Kenny, S., . . . Maughan, T. S. (2009). Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.. British journal of cancer, 100(2), 251-258. doi:10.1038/sj.bjc.6604877
2008
Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
Adams, R., Meade, A., Wasan, H., Griffiths, G., & Maughan, T. (2008). Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.. Expert review of anticancer therapy, 8(8), 1237-1245. doi:10.1586/14737140.8.8.1237
Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer.
Mukherjee, S., Hudson, E., Reza, S., Thomas, M., Crosby, T., & Maughan, T. (2008). Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 20(7), 535-540. doi:10.1016/j.clon.2008.02.003
Funding cancer treatments: Ethics of PCT decision making on funding cancer treatments
Maughan, T. S., & Rule, J. (2008). Funding cancer treatments: Ethics of PCT decision making on funding cancer treatments. BMJ, 337(7666), 367-368.
Ethics of PCT decision making on funding cancer treatments.
Maughan, T. S., & Rule, J. (2008). Ethics of PCT decision making on funding cancer treatments.. BMJ (Clinical research ed.), 337, a1243. doi:10.1136/bmj.a1243
Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
Hudson, E., Westmoreland, D., Gorman, C., Poynton, C. H., Lester, J. F., & Maughan, T. S. (2008). Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.. Chemotherapy, 54(3), 242-244. doi:10.1159/000140469
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
Moe, M., Micallef, R. A., Pwint, T., Maughan, T., Mort, D., & Wagstaff, J. (2008). Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(15_suppl), 14623. doi:10.1200/jco.2008.26.15_suppl.14623
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J. -Y., Hecker, H., Stephens, R. J., . . . Köhne, C. -H. (2008). Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(9), 1443-1451. doi:10.1200/jco.2007.14.0509
Colon and rectum
Adams, R., Maughan, T., & Crosby, T. (2008). Colon and rectum. In Practical Clinical Oncology (pp. 159-173). Cambridge University Press. doi:10.1017/cbo9780511545375.014
Challenges in Colorectal Cancer
Scholefield, J. H., Grothey, A., Abcarian, H., & Maughan, T. (Eds.) (2006). Challenges in Colorectal Cancer. Wiley. doi:10.1002/9780470753231
2007
O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2). Critical Reviews in Oncology/Hematology, 64, S32-S33. doi:10.1016/s1040-8428(13)70169-0
8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). 8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2). European Journal of Cancer Supplements, 5(6), 14. doi:10.1016/s1359-6349(07)70106-4
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., . . . National Cancer Research Institute Colorectal Clinical Studies Group. (2007). Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.. Lancet (London, England), 370(9582), 143-152. doi:10.1016/s0140-6736(07)61087-3
An audit of outcome of pancreatic cancer in a UK region: Does chemoradiation add to systemic chemotherapy for locally advanced disease
Hudson, E., Mukherjee, S., Reza, S., Thomas, M., Crosby, T., & Maughan, T. (2007). An audit of outcome of pancreatic cancer in a UK region: Does chemoradiation add to systemic chemotherapy for locally advanced disease. Journal of Clinical Oncology, 25(18_suppl), 15021. doi:10.1200/jco.2007.25.18_suppl.15021
Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial
Seymour, M. T., Maughan, T. S., Wasan, H. S., Brewster, A. E., Shepherd, S. F., O'Mahoney, M. S., . . . Langley, R. E. (2007). Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. Journal of Clinical Oncology, 25(18_suppl), 9030. doi:10.1200/jco.2007.25.18_suppl.9030
Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial
Maughan, T. (2007). Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. Journal of Clinical Oncology, 25(18_suppl), 4070. doi:10.1200/jco.2007.25.18_suppl.4070
Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J. Y., Stephens, R. J., Van Cutsem, E., . . . Köhne, C. H. (2007). Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology, 25(18_suppl), 4071. doi:10.1200/jco.2007.25.18_suppl.4071
A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.
Adams, R., Morgan, M., Mukherjee, S., Brewster, A., Maughan, T., Morrey, D., . . . Crosby, T. (2007). A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33(3), 307-313. doi:10.1016/j.ejso.2006.10.026
Patterns of Recurrence after Definitive Chemo-radiotherapy for Oesophageal Carcinoma
Button, M. R., Morgan, C. A., Croydon, E. S., Brewster, A. E., Maughan, T. S., & Crosby, T. D. L. (2007). Patterns of Recurrence after Definitive Chemo-radiotherapy for Oesophageal Carcinoma. Clinical Oncology, 19(3), S25. doi:10.1016/j.clon.2007.01.343
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
Adams, R., & Maughan, T. (2007). Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.. Expert review of anticancer therapy, 7(4), 503-518. doi:10.1586/14737140.7.4.503
Small cell oesophageal carcinoma: an institutional experience and review of the literature.
Hudson, E., Powell, J., Mukherjee, S., Crosby, T. D. L., Brewster, A. E., Maughan, T. S., . . . Lester, J. F. (2007). Small cell oesophageal carcinoma: an institutional experience and review of the literature.. British journal of cancer, 96(5), 708-711. doi:10.1038/sj.bjc.6603611
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones, R., Falk, S., Maughan, T. S., Meadows, H. M., & Sebag-Montefiore, D. (2007). A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.. British journal of cancer, 96(4), 551-558. doi:10.1038/sj.bjc.6603570
2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy, J., Douillard, J. -Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustová, I., . . . Garrison, L. P. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.. British journal of cancer, 94(8), 1122-1129. doi:10.1038/sj.bjc.6603059
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
Glynne-Jones, R., Sebag-Montefiore, D., Maughan, T. S., Falk, S. J., & McDonald, A. C. (2006). A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 17(1), 50-56. doi:10.1093/annonc/mdj031
2005
Shock and Awe
Maughan, T. (2005). Shock and Awe. Commercial Motor, 202(5158), 46-51.
Keys to success
Maughan, T. (2005). Keys to success. Commercial Motor, 202(5157), 64-65.
Small is beautiful
Maughan, T. (2005). Small is beautiful. Commercial Motor, 202(5157), 50-52.
In unity is strength
Maughan, T. (2005). In unity is strength. Commercial Motor, 202(5155), 50-52.
Information needs of cancer patients and its impact on patient outcomes
Salek, S., Al-Mohammadi, A., Nicholls, P. J., Maughan, T., & Mason, M. (2005). Information needs of cancer patients and its impact on patient outcomes. Journal of Applied Therapeutic Research, 5(4), 3-5.
Put out the right message
Maughan, T. (2005). Put out the right message. Commercial Motor, 202(5154), 64-65.
The wood from the trees
Maughan, T. (2005). The wood from the trees. Commercial Motor, 202(5153), 54-57.
Wheels within wheels
Maughan, T. (2005). Wheels within wheels. Commercial Motor, 202(5151), 52-57.
Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome.
Katugampola, R. P., Finlay, A. Y., Harper, J. I., Dojcinov, S., & Maughan, T. S. (2005). Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome.. The British journal of dermatology, 153(5), 1041-1046. doi:10.1111/j.1365-2133.2005.06839.x
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
Sebag-Montefiore, D., Glynne-Jones, R., Falk, S., Meadows, H. M., & Maughan, T. (2005). A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.. British journal of cancer, 93(9), 993-998. doi:10.1038/sj.bjc.6602818
Retention attention
Maughan, T. (2005). Retention attention. Commercial Motor, 202(5150), 64-65.
Sky's the limit
Maughan, T. (2005). Sky's the limit. Commercial Motor, 202(5150), 52-55.
Waste not want not
Maughan, T. (2005). Waste not want not. Commercial Motor, 202(5148), 42-47.
Certified practitioners
Maughan, T. (2005). Certified practitioners. Commercial Motor, 202(5146), 64-65.
The prices is right!
Maughan, T. (2005). The prices is right!. Commercial Motor, 202(5145), 58-63.
The internet highway
Maughan, T. (2005). The internet highway. Commercial Motor, 202(5142), 64-65.
NG IT MPLE
Maughan, T. (2005). NG IT MPLE. Commercial Motor, 202(5141), 57-60.
Paper chase
Maughan, T. (2005). Paper chase. Commercial Motor, 202(5139), 48-52.
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert, S., Tabernero, J., Chosidow, O., Dirschka, T., Elsner, J., Mancini, L., . . . Layton, A. (2005). The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 3(8), 599-606. doi:10.1111/j.1610-0387.2005.05058.x
New horizons
Maughan, T. (2005). New horizons. Commercial Motor, 202(5138), 64-65.
Trailer parc
Maughan, T. (2005). Trailer parc. Commercial Motor, 202(5137), 40-43.
Eastern promise
Maughan, T. (2005). Eastern promise. Commercial Motor, 201(5135), 50-55.
The army game
Maughan, T. (2005). The army game. Commercial Motor, 201(5134), 24.
Danger money
Maughan, T. (2005). Danger money. Commercial Motor, 201(5133), 64-65.
Waisting away
Maughan, T. (2005). Waisting away. Commercial Motor, 201(5133), 22.
The route masters
Maughan, T. (2005). The route masters. Commercial Motor, 201(5132), 46-49.
The clothes show
Maughan, T. (2005). The clothes show. Commercial Motor, 201(5131), 50-55.
Preoperative radiation and irinotecan in combination with 5 fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer (LARC)
Sebag-Montefiore, D., Falk, S., Glynne-Jones, R., Maughan, T., & Meadows, H. M. (2005). Preoperative radiation and irinotecan in combination with 5 fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 23(16_suppl), 3576. doi:10.1200/jco.2005.23.16_suppl.3576
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)
Glynne-Jones, R., Sebag-Montefiore, D., Samuel, L., Falk, S., Maughan, T., & McDonald, A. (2005). Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 23(16_suppl), 3527. doi:10.1200/jco.2005.23.16_suppl.3527
Empire building
Maughan, T. (2005). Empire building. Commercial Motor, 201(5130), 50-53.
Fitting in
Maughan, T. (2005). Fitting in. Commercial Motor, 201(5129), 64.
The show must go on
Maughan, T. (2005). The show must go on. Commercial Motor, 201(5027), 56-61.
Travelling light
Maughan, T. (2005). Travelling light. Commercial Motor, 201(5026), 28-29.
Engineering your career
Maughan, T. (2005). Engineering your career. Commercial Motor, 201(5025), 64-65.
Fund managers
Maughan, T. (2005). Fund managers. Commercial Motor, 201(5024), 60-62.
Special forces
Maughan, T. (2005). Special forces. Commercial Motor, 201(5022), 84-87.
Honoured veterans
Maughan, T. (2005). Honoured veterans. Commercial Motor, 201(5020), 48-51.
Safety first
Maughan, T. (2005). Safety first. Commercial Motor, 201(5018), 54-59.
Concrete to cows
Maughan, T. (2005). Concrete to cows. Commercial Motor, 201(5017), 46-51.
Senior service
Maughan, T. (2005). Senior service. Commercial Motor, 201(5015), 56-61.
Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.
Hoskin, P. J., Smith, P., Maughan, T. S., Gilson, D., Vernon, C., Syndikus, I., . . . British National Lymphoma Investigation. (2005). Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.. Clinical oncology (Royal College of Radiologists (Great Britain)), 17(1), 47-53. doi:10.1016/j.clon.2004.07.004
Meet the extendibles
Maughan, T. (2005). Meet the extendibles. Commercial Motor, 201(5013), 60-65.
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea, D. W., Nortier, J. W. R., Ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., . . . Punt, C. J. A. (2005). A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.. Annals of oncology : official journal of the European Society for Medical Oncology, 16(7), 1123-1132. doi:10.1093/annonc/mdi227
Does student teaching harm or help cancer patients?
Finlay, I., Maughan, T., & Williams, S. (2005). Does student teaching harm or help cancer patients?. Medical education, 39(11), 1166-1167. doi:10.1111/j.1365-2929.2005.02297.x
The Assisted Dying for the Terminally Ill Bill 2004.
Kenwright, S. (2005). The Assisted Dying for the Terminally Ill Bill 2004.. Clinical medicine (London, England), 5(2), 185. doi:10.7861/clinmedicine.5-2-185
2004
Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)
Glynne-Jones, R., Sebag-Montefiore, D., McDonald, A., Falk, S., & Maughan, T. (2004). Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 22(14_suppl), 3575. doi:10.1200/jco.2004.22.90140.3575
Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)
Glynne-Jones, R., Sebag-Montefiore, D., McDonald, A., Falk, S., & Maughan, T. (2004). Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Journal of Clinical Oncology, 22(14_suppl), 3575. doi:10.1200/jco.2004.22.14_suppl.3575
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts)
Díaz-Rubio, E., Burris, H., Douillard, J. Y., Coxon, F. Y., Maughan, T., Bertetto, O., . . . Scheithauer, W. (2004). Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). Journal of Clinical Oncology, 22(14_suppl), 3737. doi:10.1200/jco.2004.22.90140.3737
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts)
Díaz-Rubio, E., Burris, H., Douillard, J. Y., Coxon, F. Y., Maughan, T., Bertetto, O., . . . Scheithauer, W. (2004). Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). Journal of Clinical Oncology, 22(14_suppl), 3737. doi:10.1200/jco.2004.22.14_suppl.3737
Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?
Brown, G., Davies, S., Williams, G. T., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., . . . Maughan, T. S. (2004). Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?. British journal of cancer, 91(1), 23-29. doi:10.1038/sj.bjc.6601871
Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
Crosby, T. D. L., Brewster, A. E., Borley, A., Perschky, L., Kehagioglou, P., Court, J., & Maughan, T. S. (2004). Definitive chemoradiation in patients with inoperable oesophageal carcinoma.. British journal of cancer, 90(1), 70-75. doi:10.1038/sj.bjc.6601461
2003
The clinical impact of expert pathological review on lymphoma management: a regional experience.
Lester, J. F., Dojcinov, S. D., Attanoos, R. L., O'Brien, C. J., Maughan, T. S., Toy, E. T., & Poynton, C. H. (2003). The clinical impact of expert pathological review on lymphoma management: a regional experience.. British journal of haematology, 123(3), 463-468. doi:10.1046/j.1365-2141.2003.04629.x
277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial
Punt, C. J. A., Nortier, J. W. R., ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., . . . Rea, D. W. (2003). 277 Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial. European Journal of Cancer Supplements, 1(5), S85. doi:10.1016/s1359-6349(03)90310-7
Case report: Squamous carcinoma in an oesophageal foregut cyst.
Jacob, R., Hawkes, N. D., Dallimore, N., Butchart, E. G., Thomas, G. A. O., & Maughan, T. S. (2003). Case report: Squamous carcinoma in an oesophageal foregut cyst.. The British journal of radiology, 76(905), 343-346. doi:10.1259/bjr/30574796
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Maughan, T. S., James, R. D., Kerr, D. J., Ledermann, J. A., Seymour, M. T., Topham, C., . . . Medical Research Council Colorectal Cancer Group. (2003). Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.. Lancet (London, England), 361(9356), 457-464. doi:10.1016/s0140-6736(03)12461-0
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu, S., Georgoulias, V., Kerr, D., Maughan, T., Labianca, R., & Ychou, M. (2003). Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.. Annals of oncology : official journal of the European Society for Medical Oncology, 14 Suppl 2, ii25-ii29. doi:10.1093/annonc/mdg725
2002
RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER
Berlin, J. D. (2002). RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER. Evidence-Based Gastroenterology, 3(3), 84-85. doi:10.1097/00132579-200208000-00006
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., . . . Fielding, J. W. L. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.. British journal of cancer, 86(12), 1864-1870. doi:10.1038/sj.bjc.6600310
Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
Hale, J. P., Cohen, D. R., Maughan, T. S., & Stephens, R. J. (2002). Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.. British journal of cancer, 86(11), 1684-1690. doi:10.1038/sj.bjc.6600273
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
Maughan, T. S., James, R. D., Kerr, D. J., Ledermann, J. A., McArdle, C., Seymour, M. T., . . . British MRC Colorectal Cancer Working Party. (2002). Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.. Lancet (London, England), 359(9317), 1555-1563. doi:10.1016/s0140-6736(02)08514-8
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating, M. J., Cazin, B., Coutré, S., Birhiray, R., Kovacsovics, T., Langer, W., . . . Hérait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20(1), 205-213. doi:10.1200/jco.2002.20.1.205
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T. S., . . . Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.. European journal of cancer (Oxford, England : 1990), 38(4), 478-486. doi:10.1016/s0959-8049(01)00413-0
2001
Adjuvant chemotherapy for colorectal cancer.
Maughan, T. S. (2001). Adjuvant chemotherapy for colorectal cancer.. British journal of cancer, 85(10), 1422-1424. doi:10.1054/bjoc.2001.2081
Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial
Maughan, T. S., James, R. J., Kerr, D. J., Ledermann, J., McArdle, C., Seymour, M., . . . Stephens, R. J. (2001). Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial. European Journal of Cancer, 37, S271. doi:10.1016/s0959-8049(01)81493-3
Portfolio learning with cancer patients: an integrated module in undergraduate medical education.
Maughan, T. S., Finlay, I. G., & Webster, D. J. (2001). Portfolio learning with cancer patients: an integrated module in undergraduate medical education.. Clinical oncology (Royal College of Radiologists (Great Britain)), 13(1), 44-49. doi:10.1053/clon.2001.9213
2000
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Anderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., . . . Carmichael, J. (2000). Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.. British journal of cancer, 83(4), 447-453. doi:10.1054/bjoc.2000.1307
1999
Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe.
Bowrey, D. J., Clark, G. W., Roberts, S. A., Maughan, T. S., Hawthorne, A. B., Williams, G. T., & Carey, P. D. (1999). Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe.. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 12(4), 258-263. doi:10.1046/j.1442-2050.1999.00071.x
Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus.
Bowrey, D. J., Clark, G. W., Roberts, S. A., Hawthorne, A. B., Maughan, T. S., Williams, G. T., & Carey, P. D. (1999). Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus.. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 3(5), 462-467. doi:10.1016/s1091-255x(99)80098-5
1998
Clinical and endoscopic response to neoadjuvant therapy for carcinoma of the esophagus
Bowrey, D. J., Clark, G. W. B., Roberts, S. A., Maughan, T. S., Hawthorne, A. B., & Carey, P. D. (1998). Clinical and endoscopic response to neoadjuvant therapy for carcinoma of the esophagus. Gastroenterology, 114, A568. doi:10.1016/s0016-5085(98)82311-1
A randomized controlled study of portfolio learning in undergraduate cancer education.
Finlay, I. G., Maughan, T. S., & Webster, D. J. (1998). A randomized controlled study of portfolio learning in undergraduate cancer education.. Medical education, 32(2), 172-176. doi:10.1046/j.1365-2923.1998.00160.x
Combined modality treatment in oesophageal carcinoma.
Maughan, T. S., & Crosby, T. D. (1998). Combined modality treatment in oesophageal carcinoma.. Clinical oncology (Royal College of Radiologists (Great Britain)), 10(6), 354-355. doi:10.1016/s0936-6555(98)80028-9
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
Judson, I., Maughan, T., Beale, P., Primrose, J., Hoskin, P., Hanwell, J., . . . Sutcliffe, F. (1998). Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).. British journal of cancer, 78(9), 1188-1193. doi:10.1038/bjc.1998.652
1997
OP13. Economics of the MRC colorectal working party CR06 trial
Hale, J., Cohen, D., & Maughan, T. (1997). OP13. Economics of the MRC colorectal working party CR06 trial. European Journal of Cancer, 33, S5. doi:10.1016/s0959-8049(97)85892-3
24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)
Anderson, H., Cottier, B., Nicolson, M., Milroy, R., Maughan, T., Bond, M., . . . Thatcher, N. (1997). 24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 18, 9. doi:10.1016/s0169-5002(97)89303-8
Laparoscopic cholecystectomy: incidental carcinoma of the gallbladder with abdominal wall and axillary node metastasis.
Johnson, R. C., Fligelstone, L. J., Wheeler, M. H., Horgan, K., & Maughan, T. S. (1997). Laparoscopic cholecystectomy: incidental carcinoma of the gallbladder with abdominal wall and axillary node metastasis.. HPB surgery : a world journal of hepatic, pancreatic and biliary surgery, 10(3), 169-171. doi:10.1155/1997/60975
1996
Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Melcher, A. A., Mort, D., & Maughan, T. S. (1996). Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.. British journal of cancer, 74(10), 1651-1654. doi:10.1038/bjc.1996.604
1995
1119 Glycyl-glutamine supplemention and high dose therapy
Maughan, T. S., Poynton, C. H., Hanson, J., Shelley, M., Jebb, S., & Elya, M. (1995). 1119 Glycyl-glutamine supplemention and high dose therapy. European Journal of Cancer, 31, S234. doi:10.1016/0959-8049(95)96365-k
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
Hanna, C. L., McKinna, F. E., Williams, L. B., Morrey, D., Adams, M., Mason, M. D., & Maughan, T. S. (1995). High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.. British journal of cancer, 72(3), 774-776. doi:10.1038/bjc.1995.409
1994
Basic principles of radiotherapy for surgical oncologists. 6--Patient selection.
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 6--Patient selection.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(6), 705-710.
Minimally invasive surgery. May disseminate undiagnosed tumor.
Johnson, R. C., Fligelstone, L. J., & Maughan, T. S. (1994). Minimally invasive surgery. May disseminate undiagnosed tumor.. BMJ (Clinical research ed.), 308(6922), 199. doi:10.1136/bmj.308.6922.199
5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
Jebb, S. A., Osborne, R. J., Maughan, T. S., Mohideen, N., Mack, P., Mort, D., . . . Elia, M. (1994). 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.. British journal of cancer, 70(4), 732-735. doi:10.1038/bjc.1994.385
Basic principles of radiotherapy for surgical oncologists. 1--Effects of radiotherapy on superficial tissues. Implications for treating skin cancer.
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 1--Effects of radiotherapy on superficial tissues. Implications for treating skin cancer.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(1), 74-79.
Basic principles of radiotherapy for surgical oncologists. 2--Effects of radiotherapy on deeper tissues as illustrated by the treatment of breast cancer.
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 2--Effects of radiotherapy on deeper tissues as illustrated by the treatment of breast cancer.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(2), 168-174.
Basic principles of radiotherapy for surgical oncologists. 4--Fractions, photons and the future.
Maughan, T. S. (1994). Basic principles of radiotherapy for surgical oncologists. 4--Fractions, photons and the future.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 20(4), 484-492.
Bone marrow scintigraphy in small cell carcinoma of the lung.
Li, D. J., Maughan, T. S., Miles, K. A., & Wraight, E. P. (1994). Bone marrow scintigraphy in small cell carcinoma of the lung.. Nuclear medicine communications, 15(1), 29-33. doi:10.1097/00006231-199401000-00006
Portfolio learning: a proposal for undergraduate cancer teaching.
Finlay, I. G., Maughan, T. S., & Webster, D. J. (1994). Portfolio learning: a proposal for undergraduate cancer teaching.. Medical education, 28(1), 79-82. doi:10.1111/j.1365-2923.1994.tb02690.x
1993
Polychemotherapy in advanced non-small-cell lung cancer.
Rodger, A. (1993). Polychemotherapy in advanced non-small-cell lung cancer.. Lancet (London, England), 342(8873), 740-741. doi:10.1016/0140-6736(93)91733-3
Adverse reactions to Campath-1H monoclonal antibody.
Poynton, C. H., Mort, D., & Maughan, T. S. (1993). Adverse reactions to Campath-1H monoclonal antibody.. Lancet (London, England), 341(8851), 1037. doi:10.1016/0140-6736(93)91139-d
Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer.
Falk, S. J., Maughan, T. S., Laurence, V. M., Lamont, A., Boote, D., Ford, J. M., . . . Bleehen, N. M. (1993). Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer.. Clinical oncology (Royal College of Radiologists (Great Britain)), 5(2), 85-88. doi:10.1016/s0936-6555(05)80852-0
1992
The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma.
Wraight, E. P., Bard, D. R., Maughan, T. S., Knight, C. G., & Page-Thomas, D. P. (1992). The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma.. The British journal of radiology, 65(770), 112-118. doi:10.1259/0007-1285-65-770-112
The Use of Derivatives of α-MSH for Targeting to Melanomas In Vivo
Bard, D. R., Knight, C. G., Page-Thomas, D. P., Wraight, E. P., & Maughan, T. S. (1992). The Use of Derivatives of α-MSH for Targeting to Melanomas In Vivo. In Targeting of Drugs 3 (pp. 1-8). Springer US. doi:10.1007/978-1-4615-2938-5_1
Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.
Maughan, T. S., Ward, R., Dennis, I., Honess, D. J., Workman, P., & Bleehen, N. M. (1992). Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.. British journal of cancer, 66(3), 579-582. doi:10.1038/bjc.1992.317
1991
The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Bleehen, N. M., Maughan, T. S., Workman, P., Newman, H. F., Stenning, S., & Ward, R. (1991). The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 20 Suppl 1, 137-142. doi:10.1016/0167-8140(91)90201-q
1990
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan, T. S., Newman, H. F., Bleehen, N. M., Ward, R., & Workman, P. (1990). Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).. International journal of radiation oncology, biology, physics, 18(5), 1151-1156. doi:10.1016/0360-3016(90)90452-p
OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment.
Maughan, T. S., Haylock, B., Hayward, M., Facey, P., Evans, W. D., Shelley, M. D., . . . Adams, M. (1990). OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment.. Clinical oncology (Royal College of Radiologists (Great Britain)), 2(4), 199-205. doi:10.1016/s0936-6555(05)80168-2
1989
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen, N. M., Newman, H. F., Maughan, T. S., & Workman, P. (1989). A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).. International journal of radiation oncology, biology, physics, 16(4), 1093-1096. doi:10.1016/0360-3016(89)90924-3
CA125 in ovarian tumour tissue at second laparotomy.
Maughan, T. S., Fish, R. G., Shelley, M. D., Jasani, B., Williams, G. T., & Adams, M. (1989). CA125 in ovarian tumour tissue at second laparotomy.. British journal of cancer, 59(2), 259-260. doi:10.1038/bjc.1989.54
Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
Workman, P., Ward, R., Maughan, T. S., Newman, H. F., & Bleehen, N. M. (1989). Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.. International journal of radiation oncology, biology, physics, 17(1), 177-181. doi:10.1016/0360-3016(89)90386-6
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Kerr, D. J., Maughan, T., Newlands, E., Rustin, G., Bleehen, N. M., Lewis, C., & Kaye, S. B. (1989). Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.. British journal of cancer, 60(1), 104-106. doi:10.1038/bjc.1989.230
1988
Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.
Maughan, T. S., Fish, R. G., Shelley, M., Jasani, B., Williams, G. T., & Adams, M. (1988). Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.. Gynecologic oncology, 30(3), 342-346. doi:10.1016/0090-8258(88)90248-x
1987
The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.
Fish, R. G., Shelley, M. D., Maughan, T., Rocker, I., & Adams, M. (1987). The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.. European journal of cancer & clinical oncology, 23(6), 831-835. doi:10.1016/0277-5379(87)90287-2
1984
Infants in Juba, southern Sudan: the first twelve months of life.
Woodruff, A. W., Adamson, E. A., Suni, A. E., Maughan, T. S., Kaku, M., & Bundru, N. (1984). Infants in Juba, southern Sudan: the first twelve months of life.. Lancet (London, England), 2(8401), 506-509. doi:10.1016/s0140-6736(84)92577-7
1983
Round the World
Maughan, T. S., & Lorenz, W. (1983). Round the World. The Lancet, 322(8357), 1016-1017. doi:10.1016/s0140-6736(83)90991-1